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Abstract 
 
 Spinal muscular atrophy (SMA) is an autosomal recessive 
neurodegenerative disorder that is the leading genetic cause of infantile death.  
SMA is caused by homozygous deletion or mutation of the survival of motor 
neuron 1 gene (SMN1).  The SMN2 gene is nearly identical to SMN1, however is 
alternatively spliced.  The close relationship to SMN1 results in SMN2 being a 
very power genetic modifier of SMA disease severity and a target for therapies.  
In this study we attempt to characterize novel chemical compounds identified as 
potential activators of the SMN2 gene.  Additionally, we sought to determine the 
regulatory role individual HDAC proteins use to control expression of full length 
protein from the SMN2 gene. 
 We used quantitative PCR to determine the effects of novel compounds 
and shRNA silencing of individual HDACs on the steady state levels of a SMN2-
luciferase reporter transcripts.  We determined that the compounds identified in 
multiple reporter high throughput screens increased SMN protein levels via 
transcriptional activation of the SMN2 gene.  Other compounds identified in the 
same screen functioned post-transcriptionally, possibly stabilizing the SMN 
protein itself by decreasing degradation. Furthermore, we determined that 
reduction of individual HDAC proteins was sufficient to increase SMN protein 
levels in a transgenic reporter system.  Knockdown of class I HDAC proteins 
preferentially activated the reporter by increased promoter transcription.  
vii 
 
Silencing of class II HDAC proteins maintained transcriptional activity; however 
silencing of HDAC 5 and 6 also appeared to enhance inclusion of an alternatively 
spliced exon.  This collective work defines a quantitative RNA based protocol to 
determine mechanism of SMN reporter increase in response to any chosen 
treatment method. Additionally, this work highlights HDAC proteins 2 and 6 as 
excellent investigative targets.  These data are important to the basic 
understanding of SMN expression regulation and the refinements of current 
therapeutic compounds as well as the development of novel SMA therapeutics. 
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Spinal Muscular Atrophy 
 
Spinal Muscular Atrophy (SMA) is an autosomal recessive disease that is 
primarily described by the degeneration of the anterior horn cells of the spinal 
cord.  SMA is the leading genetic cause of infantile death [1, 2]. It is classified 
into five clinical types delineated by age of onset and developmental milestones 
that the patient is capable of achieving.  The types of SMA in decreasing order of 
severity are Type 0, acute infantile (Type I), chronic infantile (Type II), chronic 
juvenile (Type III), and adult-onset SMA (Type IV) [3-5].  There is no evidence of 
a variability of incidence within geographic or racial boundaries.  However, there 
is a noteworthy preference of males over females born with SMA [6]. 
Type 0 SMA is classified as a severe form of Type I, where diagnosis is 
made late in pregnancy and little movement and breathing is present following 
birth.  Acute infantile SMA, also known as Werdnig-Hoffmann disease, has an 
carrier frequency of 1 in 35 and an incidence of 1 in 10,000 live births [7].  Type I 
infants can appear healthy and normal at birth, however symptom onset is 
typically before 6 months of age and the life expectancy of the child is less than 
two years of age [8].  Skeletal muscle weakness progresses rapidly, resulting in 
lack of head control and weakened arm and leg movements.  Disease severity is 
compounded by respiratory and feeding complications caused by difficulty 
swallowing and weakened bulbar muscles.  Patients are never able to gain the 
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ability to sit without assistance or stand.   Increased susceptibility to respiratory 
infection ultimately leads to death as the result of respiratory failure. 
Patients with the less severe forms of SMA all present with similar 
symptoms as Type I SMA, where the severity of symptoms is inversely 
proportional to the clinical type.  The incidence of Type II and III SMA is 
approximately 1 in 24,000 births.  Chronic infantile SMA is typically first 
diagnosed prior to 18 months of age and patients are capable of head motor 
control.  The ability to sit independently can be achieved but is significantly 
delayed.  Type II SMA can also result in involuntary movement of the muscles in 
the arm, leg, and mouth.  Patients suffer some level of respiratory and feeding 
complications, however to a lesser extent than Type I symptoms [5, 9, 10].  
Chronic juvenile SMA patients and Type IV patients typically achieve all of the 
Type II milestones in addition to independent ambulatory movement at some 
point in their life.  The lifespan of these two types can be considered of average 
length.  The line separating Type III and Type IV SMA is highly dependent on 
age of onset [11].  In the most prevalent forms of SMA, type I through III, the 
causative genetic element has been linked to genomic locus 5q13 [12-15]. 
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The Genetics of Spinal Muscular Atrophy 
 
Spinal muscular atrophy is linked to homozygous deletion or mutation of 
the Survival of Motor Neuron 1 (SMN1) gene located on chromosome 5 [16].  In 
humans four genes in the region of chromosome 5q13 are maintained in 2 
copies, the result of a large scale inverted gene duplication event [17].  The 
second copy of the SMN1 is named Survival of Motor Neuron 2 (SMN2).  The 
protein product of the SMN2 gene is unstable and incapable of compensating for 
the loss of SMN1 [18].  Loss of both genes presumably results in early embryonic 
lethality.  Mice only carry one copy of the SMN gene, most equivalent to human 
SMN1, and loss of mutation of this gene is embryonic lethal [19].   
SMN1 produces a ubiquitously expressed 38 kDa, 294 amino acid protein 
localized to both the nucleus and cytoplasm [20-22].  SMN1 produces a mRNA 
that encodes 9 exons (1, 2a, 2b, 3-8) with a translation termination codon in exon 
7 [11, 16].  The 3-dimensional structure of SMN is unknown; however functional 
studies have revealed multiple distinct domains (Figure I.1).  Exons 2a and 2b 
encompass a nucleic acid binding domain, a weak oligomerization domain, and 
the binding site for Gemin2 [23-25].  The carboxy-terminus of SMN there is a 
second stronger oligomerization domain as well as a poly-proline tract [23, 26].  
In greater than 90 % of all SMA cases SMN1 is homozygous deleted.  In the 
other disease cases there are mutations or deletions within the SMN1 gene.  
There is a wide spectrum of the clinical type of SMA associated  
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Figure 1.1. SMN Protein Domain Architecture. A diagram depicting the domain 
dimensional structure of the SMN protein.  The exon number is indicated within 
each box.  The box size roughly correlates to relative exon sizes.  Specific 
domains are highlighted above and below the diagram.   Disease causing 
mutations in the SMN protein are highlighted in red (Type I) and green (Type 
II/III).  The C-T transition between SMN1 and SMN2 at the +6 position is not 
indicated as this change is translationally silent. 
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with each of these mutations.  Many of the mutations fall into the Gemin2 protein 
binding domain, Tudor domain, and the exon 6 oligomerization domain [27].  The 
Tudor domain in exon 3 mediates protein-protein and possible SMN-RNA 
interactions [28].  In most cases of SMN1 mutation disease severity is 
proportional to the degree the mutation disrupts domain function.  
In the case of homozygous deletion of the SMN1 gene, clinical type is 
inversely proportional to SMN2 copy number [29].  The additive levels of 
appropriately spliced SMN mRNA from the SMN2 genes can partially 
compensate for disruption of the SMN1 locus.  In mice it is even possible to 
completely rescue the SMA phenotype when 8 copies of the human SMN2 gene 
are introduced [30].  Increased copy number in patients can also result in some 
alleviation of symptoms and reduction of the clinical type of SMA.  It is for this 
reason that many believe that SMN2 is the best drug target for disease therapy. 
The SMN2 gene is 99.9 % identical to SMN1 starting in the promoter 
through the coding region [27, 29].  There are 5 silent mutations in the coding 
region that differentiate SMN2 from SMN1.  One of these mutations, a C to T 
transition at the +6 position of exon 7 drastically changing the mRNA transcribed 
from SMN2 [31, 32].  90% of transcripts derived from SMN2 are alternatively 
spliced and lack exon 7.  Only 10% of the SMN2 mRNAs encode the same full 
length protein dominantly produced from the SMN1 locus (Figure I.2).  SMN exon 
6 and 7 contains a critical oligomerization domain that when lacking creates an 
unstable protein that is rapidly degraded [18, 23, 33].  Therefore, despite 
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equivalently productive promoters, the SMN2 gene produces significantly less 
stable full length product than SMN1 [34].    
Splicing of pre-mRNA is dependent on the proper identification of the 5’ 
and 3’ splice sites.  A large multiprotein and RNA complex, the spliceosome, 
utilizes both cis- and trans-elements that act to enhance or silence the inclusion 
of exons in the final processed mRNA.  These sequences are bound by multiple 
proteins, but a vast number fall into the classes of serine-arginine-rich (SR) 
proteins and heterogeneous nuclear ribonucleoproteins (hnRNP).  The mutation 
at the +6 position of SMN2 exon 7 is thought to concurrently disrupt an exonic 
splicing enhancer (ESE) and strengthen an exonic splicing silencer (ESS).  In the 
first model, the +6 position of exon 7 is contained within a heptameric sequence 
that acts as an ESE [35, 36].  When a C is in this position the heptamer it acts as 
a strong binding site for the SR protein SF2/ASF that promotes exonic inclusion.  
Once bound to this sequence SF2/ASF most likely exerts its function by 
recruiting secondary splicing actors such as hnRNP G, SRp30c, and hnRNP Q.  
This complex is capable of binding and stabilizing U2AF at the intron 6 branch 
site and subsequently the U2 RNP, strengthening the weak 3’ splice site [37-39].  
Additionally, ASF/SF2 binds the U1 specific protein 70K, enhancing the primary 
detection of the 5’ splice site of intron 7 by the U1 RNP[38]. The introduction of a 
T in the +6 position of exon 7 interrupts the ESE and any enhancement given by 
this site is lost.   
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Figure I.2. Alternative Splicing of SMN2.  A graphical representation of the 
effect a C to T mutation has on the splicing of SMN2 exon 7 in comparison to 
SMN1. The 500 Kb genomic DNA region and inverted duplicate are represented.  
Pre-mRNA with relative sizes of introns and the predominant splicing pattern of 
SMN1 and SMN2 are depicted.  RT-PCR of SMN1 and SMN2 genes show the 
ratio of exon 7 included (top band) to excluded (bottom band).  The majority of 
transcripts expressed from SMN1 retain exon 7 while SMN2 transcripts are 
inverted. Obtained from Lorson CL et al. Hum. Mol Genet. 2010. 
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An alternative model conversely suggests that the C to T transition creates 
an ESS.  This site is bound by hnRNP A1 and the weak exon 7 is excluded.  The 
presence of hnRNP A1 inhibits binding of the 5’ splice site of intron 7and the 
intron 6 branch point by splicing RNPs [40, 41].  This is achieved through direct 
steric interference or secondary disruption of another known ESE 
downstream of the ESS bound by hTra2β.  Additional inhibitory contribution by 
Far Upstream Element (FUSE) blocking the branch point in intron 6 further 
promotes exon 7 skipping (Figure I.3) [42].  While both of these models have 
supporting data, it is entirely likely that exon 7 splicing regulation is not mutually 
exclusive and is a blend of both scenarios among other influencing factors.   
There are numerous secondary protein elements that have been shown to 
increase inclusion of exon 7 in addition to the ESS and ESE elements already 
mentioned.  At the 3’ terminus of exon 7, two negative elements exist that inhibit 
exonic inclusion.  The first of these elements consists of a heptameric sequence, 
termed the 3’ cluster, that when disrupted an increase in exon 7 inclusion is 
observed [40].  Downstream of this sequence a RNA secondary structural loop 
element, the terminal stem loop 2 (TSL2), when formed inhibits the proper 
splicing of the 5’ splice site of intron 7[43].  Only in the context of SMN2, where 
the C to T mutation has already created a weak exon, does this inhibitory 
structure have a striking effect on exon 7 skipping. 
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Figure I.3 Summary of Protein Elements Controlling Exon 7 Splicing.  A 
graphical representation of the region surrounding SMN exon 7 in SMN1 and 
SMN2.  A C in the +6 position of exon 7 (SMN1) is bound by the SR protein 
ASF/SF2 (blue) which promotes recognition of the branch point on intron 6 as 
well as the 3’ splice site of exon 7.  A T in the +6 position (SMN2) in bound by 
hnRNP A1 (red) which inhibits binding of the ASF/SF2 complex as well as the 3’ 
splice site.  FUSE/APB protein complex also binds and inhibits the recognition of 
intron 6 branch point.  
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SMN Function 
 
The 38 kDa SMN protein localizes to the nucleus and cytoplasm in all cell 
types [20].  In the nucleus SMN concentrates in structures rich in transcriptional 
and RNA processing machinery called gems (Gemini of Cajal bodies).  These 
structures often overlap with Cajal bodies but are considered separate structures 
[44, 45].  There are typically 1-2 gems per nucleus.  The number of gems 
observed in a population of cells correlates directly to SMN protein level and 
disease severity, with lower counts of gems in the most severe forms of SMA.  
The SMN protein is essential for gem formation; RNAi depletion results in the 
loss of detectable gem formations [46].  In the cytoplasm SMN is well distributed 
with concentration at the growth cone of axons [47-50].   
Animal models of SMA have provided insight into the potential roles SMN 
plays in neuronal outgrowth, neuromuscular junction (NMJ) formation, and 
synaptic plasticity [51-57].  In the spinal cord SMN is most highly expressed in 
anterior horn cells, the cell that is also most sensitive to low SMN levels.  An 
SMA model in zebrafish contains motor neurons that are shorter in length than 
wild-type animals and also display decreased arborization of the motor axon [58].  
In contrast, data from the severe SMA mouse model suggest that neuronal 
pathfinding is normal; however there exists an inability to form and maintain a 
functional NMJ followed by denervation and cell death [55].    
15 
 
The most characterized SMN complex is responsible for assembly of 
mature spliceosomal small nuclear ribonucleoproteins (snRNP) [25, 59].  Splicing 
of cellular mRNAs is dependent on the U1-U7 snRNPs.  Each of these snRNPs 
consists of a RNA element bound by Sm proteins and other proteins unique to 
each snRNP.  Assembly of Sm proteins onto snRNAs will occur spontaneously in 
vitro, however the SMN complex mediates this process to ensure correct, 
specific, and efficient construction in vivo[59].  To do this, SMN binds Gemin 
proteins to identify snRNAs containing Sm sites and arranges Sm proteins on the 
RNA into a heptameric ring.  The SMN complex consists of Gemin2-8, and 
UNRIP [25, 60-67].  Gemin2, 3, and 8 are directly bound to the SMN protein 
while Gemin4-7 bind via the other Gemin proteins.  Gemin5 interaction with the 
complex is most susceptible to high salt concentrations during 
immunoprecipitation and is therefore considered the weakest [68].  Gemin5 is 
also rarely detected in gems.  Gemin2, 3, and 5 knockouts in organisms from 
yeast to mouse result in lethality, suggesting the proper assembly of all 
components of the SMN complex are essential for survival.   
Following loading of the Sm proteins on the snRNA and RNA 5’ cap 
processing, the entire SMN-snRNP complex is imported in to the nucleus where 
the pairing dissolves and SMN returns to the cytoplasm to repeat the cycle.   
There is a correlation between the ability of the SMN complex to assemble 
snRNPs and disease severity [69].  Measurement of snRNP formation in the 
severe (type I) SMA mouse model reveals a significant reduction of mature 
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snRNPs [70].  There is an analogous, yet diminished, reduction of mature particle 
formation in models of less severe forms of SMA.  Concurrently, the Sm binding 
capacity of low severity mutant SMN proteins is less than wild-type protein but 
greater than delta exon 7 SMN [28].  Mutation or disruption of the SMN C-
terminal oligomerization domain severely diminishes Sm protein binding and as a 
consequence affects snRNP assembly.  It is believed that multiple SMN proteins 
complex with the Gemins and interference with oligomerization inhibits the entire 
complex formation.    
SMN has been implicated in multiple cellular processes.  However, no 
specific function of SMN has been directly tied to SMA pathogenesis.  The root of 
understanding the complexity of factors that cause SMA is determining why 
motor neurons are specifically sensitive to low SMN levels.  Two models exist 
that attempt to explain this conundrum.  First, it is possible that SMN function 
loss is universal to all cell types, however motor neurons, posses unique 
demands that render them most sensitive.  Second, it is also plausible that SMN 
possess a function that is unique to motor neurons and essential for cell survival. 
The first model of SMA pathogenesis predicts that low SMN levels result 
in a system wide reduction of snRNP formation.  Low levels of mature snRNPs 
can result in a loss of the cell’s ability to properly recognize splice sites in mRNA 
with high fidelity.  It is then plausible that in motor neurons this would result in 
alternative splicing of mRNAs that are essential to cell survival.  Exon expression 
microarrays have been used to detect aberrant splicing patterns of the spinal 
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cord and other tissues of a SMA mouse model [71, 72].  These studies observed 
alternative splicing of multiple exons across the genome in both pre- and post-
symptomatic mice.   With progression of the disease phenotype, there was a 
parallel increase in deviations from normal splicing patterns.  There were also 
differences in alternatively spliced transcripts between tissue types, supporting 
the possibility of a motor neuron-specific splicing perturbation leading to cell 
death.  However, it is unclear whether the changes in splicing preceded symptom 
onset, or whether the effects were a byproduct of the worsening symptoms.   
 A second and equally compelling hypothesis for SMA pathology theorizes 
that low SMN levels disrupt a motor neuron specific function of the protein, which 
results in cell death.  SMN complexes in neurites of tissue culture neuronal-like 
cells show high coincidence with the Gemin proteins while maintaining nearly 
complete lack of association with the Sm proteins.  This data suggests that SMN 
is imparting a function in the axon of neurons that is mutually exclusive from its 
better described role in snRNP formation. 
 Many of SMN’s published interacting partners contain RNA Recognition 
Motifs (RRMs).  Despite the lack of Sm protein in the SMN axonal complex, there 
may be a conserved function of RNP assembly and transport.  Specifically, over 
expression or depletion of the SMN binding partner, hnRNP R, has been linked 
to increased or decreased neurite outgrowth respectively [73, 74].  Expression 
levels of hnRNP R have a proportional effect on neurite length in tissue culture.  
Mutant hnRNP R that lacks either the RRM or SMN interaction domains is 
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ineffective at modulating neurite length.  Additional data suggests that SMN in 
partnership with hnRNP R forms a complex to transport β-actin mRNA into the 
neuron.  In SMA primary motor neurons the concentration of hnRNP R protein in 
the axon is reduced and there is a comparable reduction of [48, 75, 76] mRNA 
and protein at the growth cone.  The disruption of β-actin mRNA and protein in 
the growth cone offers some indication of a potential mechanism for motor 
neuron sensitivity to low SMN levels.  Reduced β-actin protein and mRNA inhibits 
the cells ability to respond to external stimulus as well as disrupting cytoskeletal 
structure of the axon.  The disruption of actin mRNA may not be a unique 
phenotype and it could suggest additional mRNAs with disrupted localization 
could exist in SMA. 
 Additionally, a neuron specific mRNA binding protein, HuD, binds SMN 
and actively co-transports into the axon [77, 78].  HuD is a part of a family of 
mRNA binding proteins expressed in post-mitotic neurons that bind the 3’ 
untranslated region and regulate stability and translation [79, 80].  HuD knockout 
mouse models have motor defects.  Interestingly, one identified target of HuD is 
β-actin mRNA [81].  Similar to hnRNP R, HuD localization into the axon is 
disrupted by low SMN levels.  In the same study, following SMN knockdown in 
primary motor neurons the gross localization of poly-A mRNA was reduced in the 
axon [77].   
 The SMN protein has also recently been demonstrated to bind the α-
subunit of the ER-Golgi coatamer complex [82].  Coatomer is a multiprotein 
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complex localized to the cytoplasm and is required for COPI vesicle budding.  
SMN and α-COP co-localize in the axons of primary mouse hippocampal 
neurons and in chick retinal neurons.  Furthermore, fluorescently tagged SMN 
and α-COP co-traffic within the neurites of cultured differentiated neurite like 
cells, SH-SY5Y.  α-COP depletion also significantly reduced the localization of 
SMN to the leading edge of the F-actin filipodia.  SMN was initially described to 
traffic in both anterograde and retrograde directions in primary hippocampal 
neurons prior to the identification of this interaction [83].  The movement was 
consistent with the fast rate of transport of microtubule based motors.   
   It is plausible to theorize that the coatamer-SMN complex in conjunction 
with RNA binding proteins, such as hnRNP R and HuD, identify and traffic 
mRNAs into the axon of motor neuron.  HuD previously reported role in mRNA 
stability and translation may also suggest a potential added complexity of the role 
of the SMN-mRNA axonal complex.  The complex may stabilize mRNA in the 
growth cone and delay translation until necessary for cellular response to 
environmental stimulus.  In SMA, low SMN levels may disrupt the formation of 
the larger complex, resulting in the impaired transport of essential mRNAs to the 
growing tip of the axon.  This defect could handicap the axons ability to adapt 
and respond to stimulus and in the case of SMA lead to neuronal degeneration. 
 There is compelling evidence for both theories of motor neuron sensitivity 
to low SMN protein levels.  The reality of SMA pathogenesis most likely lies 
between both models.  There are proven defects in splicing of neuronal specific 
20 
 
factors in SMA, and sufficient evidence in support of a mRNA transport function 
of SMN.   Low SMN levels potential disrupts mRNA biology at multiple levels 
including processing, translocation, and translation.  While it is important to 
understand SMA pathology to treat the disease, it is just as critical to explore any 
possible means to treat the disease based on current data.    
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Spinal Muscular Atrophy Treatment 
 
 Despite an incomplete understanding of SMA pathology, viable 
therapeutic targets have been identified.  There are many distinct therapeutic 
strategies to treat SMA.  Gene replacement therapy attempts to directly introduce 
addition copies of SMN1 corrects the disease causing mutation or loss of the 
gene.  Other approaches have targeted the neuron with neuroprotective 
compounds and more recently, neuronal replacement by stem cell therapy in 
mice has been investigated.  However, the most utilized strategy is to increase 
the expression from the SMN2 locus or to modify splicing of SMN2 mRNA.  As 
discussed, SMN2 gene copy number, or in this case expression, is an excellent 
modifier of SMA disease severity.  Table 1 contains a summary of compounds 
that have been or are currently in clinical trials for SMA. 
 Gavrilina [84] et al. showed that neuronal expression of SMN alone was 
sufficient to significantly increase the survival of severe SMA mouse models [84].  
Post-natal delivery of the SMN1 gene by an self complimentary adeno-
associated virus (scAAV)-9 vector successfully rescued the severe SMA mouse 
[85].  The scAAV-9 vector crosses the blood-brain barrier and transduces a high 
percentage of motor neurons.  This same study observed that there was a 
therapeutic window for scAAV-9 treatment.  There was an inverse correlation to 
the effectiveness of treatment and post-natal time.  It is unclear how this time 
period translates into SMA patients.  This may complicate any treatment  
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Table I.1. Previous SMA Clinical Trials.  A brief summary of previous SMA 
clinical trials highlighting the proposed mechanism of action in addition to the 
outcome of the studies. 
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Drug Name Mechanism of Action 
Number of 
Trials 
Type (and #) 
of Patients Results References 
Albuterol 
β-
Andrenoreceptor 
agonist 
1 Type II/III (13) ↑ Strength [86] 
Gabapentin Neuroprotection 2 Type II/III (204) Negative / ↑ 
strength [87] 
Riluzole Neuroprotection 2 Type I (51) Inconclusive [88, 89] 
Phenylbutyrate SMN2 activation 3 Type I/II (124) 
Negative/  ↑ 
mRNA and 
strength 
[90, 91] 
Acetyl-L-
Carnitine Neuroprotection 1 Type I/II (110) Negative [92] 
Creatine Neuroprotection 1 Type II/III (504) Negative [93] 
Hydroxyurea SMN2 activation 2 Type I/II/III (>33) Negative [94] 
Valproic Acid SMN2 activation 2 Type I-IV (49) ↑ 
strength/mRNA [95, 96] 
Valproic Acid / 
Acetyl-L-
Carnitine 
SMN2 activation 
/ 
Neuroprotection 
1 Type II/III (90) Negative [97] 
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considered, as in most cases SMA symptoms are not present at birth.  Any delay 
of diagnosis may reduce the efficacy of disease rescue.  The use of a viral 
delivery method is further complicated by potential immune response by the 
patient and possible secondary infection if immunosuppresion is necessary.  
However, these data provide compelling evidence that gene therapy may be 
highly effective at treating SMA. 
 Neuroprotective chemical compounds have been used with modest 
success in treatment of other motor neuron degenerative diseases including 
Amyotrophic Lateral Sclerosis (ALS) [98-102].  The neuroprotective compounds 
slow and eventually reverses the death of the motor neuron. Gabapentin, 
Riluzole, and Acetyl-L-carnitine are all neuroprotective compounds that have 
been used in current or previous SMA clinical trials [87, 89, 103].  Both 
Gabapentin and Riluzole control the release of glutamate, reducing the 
excitability of the motor neuron.  Mixed results were observed in two Gabapentin 
studies, the more successful of the studies showing only low to moderate arm 
and lower body strength increases [87].  Riluzole showed promising results 
increasing survival in a mouse model of SMA [103].  In a patient trial, the drug 
also appeared to increase survival in a small number of patients.  However, 
conclusive results from the study were limited by small sample size [89].  It is not 
clear the contribution that this class of drugs will have on long term SMA 
treatment.  The moderate improvements observed may not be sufficient alone for 
treatment, but may provide a valuable added benefit when used in combination 
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with other therapeutic strategies.  One such clinical trial has completed with 
concurrent treatment with the HDAC inhibitor valproic acid and the 
neuroprotective compound acetyl-L-carnitine.  Unfortunately, the clinical trial 
resulted in no functional benefit following 6 months of treatment [97].  
There are numerous opportunities to increase full length protein produced 
from the SMN2 locus.  Enhancing transcription from the SMN2 promoter, 
increases the total amount of SMN mRNA, both exon 7 included and excluded 
transcripts.  Post-transcriptionally, SMN protein can be increased by stabilizing 
SMN2 mRNA, modification of exon 7 alternative splicing, enhanced translation of 
full length mRNA, or stabilization of SMN protein.  Increasing the half-life of SMN 
mRNA and enhanced translation produces more protein per mRNA transcribed.  
Modulation of exon 7 splicing is potentially the most attractive method at 
increasing full length protein levels.  SMN2 is as transcriptionally active as 
SMN1, improving the splicing ratio to increase inclusion of exon 7 could be 
considered equivalent to SMN1 gene replacement [34]. 
 RNA based therapies are currently being investigated as a successful 
method to correct the exon 7 splicing defect.  Antisense oligonucleotides (ASO) 
target sequences within and flanking exon 7 to promote mRNA inclusion.  Initial 
efforts covalently coupled arginine and serine (SR) peptides to the 
complementary sequence [104].  The SR peptide presumably acted as an 
artificial ESS to recruit SR-proteins to encourage exon 7 inclusion.  These 
synthetic binding sites successfully increased exon 7 inclusion, however the rate 
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of inclusion is inefficient.  A more stable solution combined the SR-ASO with a 
U7-snRNA expression vector.  By including the U7 backbone, the SR-ASO is 
incorporated into snRNPs and better promoted inclusion [105].  U7 modification 
of the SR-ASO is very effective at ameliorating symptoms of the severe SMA 
mouse when delivered using an adenovirus delivery system similar to the scAAV-
9 expression of SMN1[106]. 
An alternative to artificially creating an ESE is to use the oligo to mask 
intronic splicing silencer sequences.  This strategy was very potent, promoting 
exon 7 inclusion at very low concentrations in primary fibroblasts.  The most 
effective target sequences is the ISS sequences flanking exon 7 [107, 108].  
Binding to the mRNA sequence competes for binding with the negative element 
hnRNP A1.  Delivery of similar ASOs into SMA mice significantly increases full 
length SMN protein in some tissues, however without significantly increasing 
survival [109].  Increased SMN protein in neuronal tissue is essential for 
increased survival.  One drawback of an ASO treatment strategy is that the 
oligos do not cross the blood brain barrier, making it very difficult to increase 
neuronal SMN protein levels.  This problem has been circumvented by using 
intracerebroventricular (ICV) delivery of the oligos directly to the nervous system 
of SMA mice [110].  Oligos were also demonstrated to be successfully 
incorporated into non-human primate neurons using similar ICV delivery.  This 
method successfully modifies the splicing of exon 7 in the central nervous system 
of severe SMA mice and has a significant impact on survival.  In a similar study 
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in type III SMA mice, the ASOs used were very stable and were found to still be 
present 6 months following the initial treatment.  It may be possible to treat SMA 
patients using ASO and improve disease symptoms with a limited number of 
treatments.  However, more investigation is needed to determine the immune 
response to ICV injected oligos and the associated safety.  Inflammation was 
observed in some studies in the spinal cord of treatment mice.   
Histone deacetylase inhibitors (HDAC) are a class of compounds effective 
at increasing SMN protein levels.  The role of HDACs and HDAC inhibitors will be 
explored further and more extensively review in the second chapter.  Briefly, 
HDAC inhibitors, phenylbutyrate, hydroxyurea, and valproic acid have all been 
tested in clinical trials with moderate strength benefit to patients without any 
enhanced survival.  Newer generation HDAC inhibitors have been generated that 
are proving to be more potent at increasing SMN protein levels.  HDAC inhibition 
is predicted to increase transcription from the SMN2 promoter as well as 
increasing the inclusion of exon 7 in the processed mRNA via increased levels of 
SMN splicing factors.   
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Work in this section was supplemented by Jonathan Cherry Ph.D. a 
current assistant professor at the Indiana University School of Medicine.  
Portions of this work have been submitted for publication and are currently under 
revision. 
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Confirmation and Validation of SMN Activating HTS drug targets 
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There is a constant need to search for new therapeutic strategies while 
current treatments are refined.  When screening for compounds that activate 
SMN2, two different strategies have been employed previously.  Both use 
artificial plasmids that combine a transgenic protein that is readily detectable with 
an endogenous element of SMN2.  One method measures transcriptional 
activation by placing the reporter gene under the control of the endogenous 
SMN2 promoter.  If any given compound results in enhanced transcription of the 
SMN2 promoter, an increase of the total signal of the reporter protein such as 
luciferase or bacterial β-lactamase is observed.  Similarly, another strategy 
utilizes a SMN2 splicing cassette to screen for compounds that modulate SMN 
exon 7 splicing.   
SMN splicing cassettes use the genomic sequence for the c-terminus of 
either SMN1 or SMN2 beginning at exon 6 through the 5’ end of exon 8 [111].  
The last exon is replaced by a reporter gene early in the sequence.  The entire 
fusion protein is under the control of the abundantly expressing Cytomegalovirus 
(CMV) promoter.  Alternative splicing of exon 7 results in a frameshift 
downstream and that prevents the translation of the reporter gene as a result of 
early termination.  Reporter signal is only detected if exon 7 is included in the 
final product.   
These two strategies have been successful at identifying new therapeutic 
compounds, as well as dissecting the mechanics of SMN expression and exon 7 
splicing.  Drug discovery with either of the two constructs limits the pool of 
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compounds that have the ability to increase SMN protein levels.  The most potent 
compounds not only increase SMN2 transcription, but also reduce skipping of 
exon 7.  These two assays completely neglect any compounds that act post-
translationally to stabilize SMN because the entire protein is not expressed in 
either reporter.  Moreover, Stable maintenance of the constructs is subject to 
silencing over time as well as possible negative effects of random integration.  It 
is possible to perform experiments with transient expression, however the 
normalization between experiments can be difficult and data can be dependent 
on transfection efficiency.     
Dr. Jonathan Cherry constructed an episomal plasmid that combines the 
utility of each of these systems.  The reporter is expressed by the SMN2 
essential 3.4 kb promoter followed by exons 1-5 cDNA cloned in frame with the 
SMN2 splicing cassette described previously [112].  In this system the entire full 
length SMN protein is translated and fused to firefly luciferase when exon 7 is 
included in the mature mRNA (Figure 1.1).  There is also a CMV driven renilla 
luciferase gene contained in the 20.1 kB pCEP4 episomal based plasmid that 
can be used for experimental normalization.  With this reporter system it is 
possible to identify increase in SMN levels regardless of the mechanisms utilized.  
The reporter attempts to mimic the endogenous gene and protein as closely as 
possible.  The reporter will respond to changes in transcription, splicing, 
translation, as well as mRNA and protein stability (Figure 1.1).   
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Figure 1.1. Newest Generation SMN2 Episomal Reporter.  Schematic 
depicting the layout of a SMN2 reporter expressing full length SMN fused to 
firefly luciferase under the control of the 3.4 kB SMN2 promoter.   
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The plasmid was introduced and maintained in the human embryonic 
kidney 293 T (HEK293T) cell line.  This strain was originally generated from 
adenovirus transformed kidney cells in culture.  Kidney cultures are not uniform  
in tissue type and it is believed that HEK293 cells are in fact of neuronal origin.    
There are substantial neuronal specific genes that are expressed in this cell type 
[113].  Therefore, HEK293T cells are an excellent human cell line to test SMN 
activating treatments and are exceptionally easy to grow at a scale necessary for 
high throughput applications.  HEK293T cells were transfected with either SMN1 
or SMN2 episomal reporter constructs and stable cell lines were established.  
There are a limited number of nucleotides that differ between the SMN2 and 
SMN1 promoters as well as intronic sequences.  These changes were conserved 
throughout the respective reporter constructs.   
 Stable reporter cell lines were selected based on luciferase fusion 
expression levels.  The SMN1-luciferase reporter cell line was observed to have 
luciferase activity levels approximately 40 fold greater than the SMN2-luciferase 
reporter cell line (Figure 1.2 A, B).  The response of the SMN2-luciferase reporter 
cell line was tested at multiple drug concentrations of suberoylanilide hydroxamic 
acid (SAHA) and sodium butyrate (Figure 1.2 D, F).  Treatment of the SMN1-
luciferase cell line with SAHA did not result in an increase of luciferase fusion 
protein.    The reporter cell lines responded robustly to known SMN activating 
compounds and therefore should be a viable tool for SMA therapy screening [90, 
114, 115]. 
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Figure 1.2. Validation of the SMN1 and SMN2 episomal reporters.  Western 
Blot and Luciferase data validating the novel SMN1 and SMN2 reporter, A3 and 
B3 respectively. (A) Relative light units of the SMN-Luciferase fusion protein in 
A3 and B3 reporter cell under normal conditions.  (B) Western-Blot data of the 
two cells lines using anti-luciferase antibody to identify the fusion protein. (C) 
SAHA treatment of A3 cells (D) SAHA and sodium butyrate treatment of B3 cells 
(E, F) Western Blot data for the same cells used in C and D.  Data and figure 
collected by Jonathan Cherry, Ph.D. (submitted data). 
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Both the SMN1 and SMN2 reporter cell lines were used in high throughput 
screens at multiple collaborating sites to identify and screen approximately 1 
million compounds for SMN activation.  5 compounds and chemical analogs were  
identified to increase luciferase activity while maintaining specificity and 
properties amicable to drug development.  Three of the HTS hits were confirmed 
to enhance SMN2 transcription while the remainder of the compounds utilized 
mechanisms of action downstream of translation. The drugs were tested in 
primary SMA patient fibroblasts and confirmed to maintain activity.  The 
development of the episomal reporter yielded many drug targets that will be 
investigated further as potential SMA therapies. 
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Materials and Methods 
 
Tissue Culture  
Cells were incubated at 37oC with 5% CO2. HEK293T cells were grown in 
D-MEM (Gibco, #11995) with 10% fetal bovine serum (Sigma) and 1x Pen-Strep 
(Gibco, #15140).  Reporter cells were grown in the same medium supplemented 
with 200 ug/mL Hygromycin B (Invitrogen, #10687-010).  Primary human SMA 
patient fibroblasts, 3813, were grown in D-MEM with 15% fetal bovine serum and 
1x Pen-Strep. 
PCR and RT-PCR 
For analysis of SMN-luciferase fusion, compounds were tested at three 
concentrations that display maximal activity in the luciferase assay.  Reporter 
cells were plated at 750,000 cells in a 6 well dish.  24 hours after plating drug 
was added to the well and cells were harvested after an additional 24 hours.  
Cells were harvested by trypsinization, neutralized with trypsin inhibitor, and 
washed.  10% of each cell pellet resuspended and plated into three wells of a 96-
well dish and was used to analyze for luciferase activity with the DualGlo 
luciferase assay).  RNA was isolated from cells using Trizol Reagent (Invitrogen, 
#15596-026).  cDNA was generated using the Improm-II Reverse Transcription 
System (Promega, #A3801).  The forward primer of the SMN amplicon binds the 
exon 5-6 junction and uses an XhoI site used to create the reporter in order to 
amplify only reporter transcripts.  The primer pair of SMN Xho-Forward and 
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Luciferase-reverse amplifies both exon 7 included and excluded transcripts.  
SMN-Xho-Forward and SMN Exon 7-Reverse is specific to exon 7 included 
transcript.  For a normalization standard we amplified a region within the 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) transcript.   
All reactions were incubated at the same Tm.  The conditions were as 
follows, 5 minutes at 95 oC followed by a cycle of 30 seconds at 95 oC, 30 
seconds at 60 oC, and 1 minute at 72 oC.  The number of cycles for GAPDH were 
25 while SMN reporter transcripts required 32. 
 
Primer Name Sequence 
Exon 5/XhoI – Forward  CATTTCCTTCTGGACCACTCGAG 
Exon 5 – Forward GCCTCCATTTCCTTCTGGACCA 
Exon 5/6 – Forward CATTTCCTTCTGGACCAATAATTCCC 
Luciferase-Reverse ATAGCTTCTGCCAACCGAACGG 
Exon 7 – Reverse TAAGGAATGTGAGCACCTTCCTTC 
Exon 8 – Reverse CTACAACACCCTTCTCACAGG 
GAPDH-Forward ACCACAGTCCATGCCATCAC 
GAPDH-Reverse TCCACCACCCTGTTGCTGTA 
 
Quantitative PCR (qPCR) 
qPCR was performed as described in the protocol for iQ SybrGreen 
Supermix (BioRad, #170-8882) in an Eppendorf Mastercycler ep Realplex 4 real-
time PCR machine.  Reactions were incubated for a 10 minute 94 oC hot start 
followed by 45 cycles of the following: 94 oC for 45 second, 60 oC for 15 seconds, 
72 oC for 45 seconds.  The Pfaffl method was used to determine the change in 
transcript levels relative to the DMSO and normalized to glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH).  A 5 point standard curve for each primer 
set was included on every plate to determine experimental deviation in primer 
efficiency.  Error bars in graphs depict SEM. 
Gem Count Assay 
 For gem count assays, 3,000 primary 3813 fibroblasts, were plated in 
each well of an 8 chambered slide (Nunc, #S6815).  24 hours after plating drug 
or DMSO carrier were added.  Media and drug were changed every 24 hours for 
72 additional hours.  Prior to fixation cells were washed twice with cold 
phosphate buffered saline (PBS).  The cells were then covered with a 1:1 fresh 
cold methanol:acetone mixture for 5 minutes.  Slides were again washed 3X with 
PBS + .2% Triton X-100 (PBS-T).  Slides were blocked overnight at 4 oC in PBS-
T + 2% BSA.  Primary antibody (Anti-SMN 4B7) was diluted 1:15 in blocking 
buffer and added to the cells for 3 hours at room temperature.  Cells were 
washed 5X with PBS-T. Secondary Alexa-488 Goat Anti-Mouse was diluted 
1:1000 in blocking buffer and added to the cells for 1 hour at room temperature 
followed by 5x PBS-T washes.  Cells were mounted with prolong Gold with DAPI 
DNA stain (Invitrogen Cat# P36931). 
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Results 
  
 The SMN2-luciferase reporter cells were active in response to the HDAC 
inhibitors SAHA and sodium butyrate.  As discussed, the reporter is highly 
versatile and effective because of the capability of identifying a diverse 
population of SMN activating compounds.  However, the ability to distinguish 
between the potential mechanisms of action is critical to validate and develop 
any treatment.  One challenge posed by the reporter cell lines is that the 
episomal construct is maintained in the HEK293T cell line which is homozygous 
for both SMN1 and SMN2.  Endogenous HEK293T SMN protein does not 
interfere with the detection of SMN-luciferase activity.  However, endogenous 
messenger RNA (mRNA), can easily contaminate specific identification of 
reporter mRNA because of the near exact sequence similarity.  It is critical not 
only to measure the levels of total reporter mRNA, but also to accurately track 
SMN exon 7 inclusion.   
 Unique sequences found in the reporter were targeted to discriminate 
against endogenous mRNA species.  The most convenient reporter specific 
feature to exploit was the firefly luciferase gene.  However, exclusive RT-PCR 
amplification of the luciferase transcript would only measure increases in 
transcription and would neglect any modification of exon 7 splicing.  Upstream of 
luciferase, the only other reporter specific feature was an XhoI restriction enzyme 
site used to clone the exons 1-5 cDNA to exon 6 of the spicing cassette.  This 
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primer was capable of binding to endogenous exon 5 sequences; however 
extension was unable to proceed without specific annealing of the XhoI 
complementary sequence.  A second primer was designed using sequence 
within exon 7 in combination with the XhoI start site to detect only transcripts that 
included exon 7 for use in SYBR green based qPCR.  A summary of these 
primers and expected products is illustrated in Figure 1.3.   
The specificity of the primers described were tested on wild-type 
HEK293T and SMN2-luciferase reporter cell mRNA (Figure 1.4).  Primers that 
amplified exon 5 or the exon 5/6 junction through exon 8 were also tested.  
Primer pairs specific to endogenous HEK293T SMN mRNA efficiently amplified 
appropriate products (Figure 1.4 lanes 1, 2, 4, 5).  For primer products spanning 
exon 7 a doublet was observed.    All other primer sets that specifically amplified 
reporter transcripts were void of any PCR product (lanes 3, 6-9).  The same set 
of primers were tested on B3 reporter cell RNA extracts (Figure 1.4 Bottom 
Panel)  Primer sets Exon 5 Forward - Exon 8 Reverse and Exon 5/6 Forward – 
Exon 8 Reverse, specific to endogenous mRNA, appeared to be less efficient in 
the reporter cells than in wild-type HEK293T cells (lanes 2,5).  This is likely due 
to quenching of the forward primer by reporter mRNA transcripts, limiting the 
direct amplification of endogenous mRNAs.  Primer sets specific to reporter 
transcripts were positive for PCR products from the reporter lysates.  In contrast, 
reactions amplifying exon 5 to luciferase in reporter lysates the major product 
was the faster migrating delta exon 7 transcript.  
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Figure 1.3.  PCR and RT-PCR Primer Pairs.  The locations of primers used to 
amplify genomic and reporter mRNA.   Primer pairs that span both intron 6 and 7 
amplify both exon 7 included and excluded transcripts (bottom pair).  Any primer 
that does not anneal to reporter derived transcripts is noted by (Genomic Only).   
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Figure 1.4. RT-PCR of Endogenous and Reporter Transcripts. Top Panel: 
Wild-type HEK293T cells, lanes 1,2,4,5 amplify products from genomic specific 
primers of expected size.  All reactions designed to amplify reporter transcripts 
are negative.  Bottom Panel:  Amplification of both genomic and reporter 
transcripts with appropriate primer pairs. 
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The SMN2 reporter yielded the appropriate ratio of exon 7 included to 
skipped mRNA.  Quantitative RT-PCR was done to quantify the exact splicing 
efficiency of the reporter transcripts.  To begin the primer efficiency of the primer 
sets Exon 5-XhoI Forward / Exon 7 Reverse, Exon5-XhoI Forward / Luciferase 
Reverse, and GAPDH were determined for both SMN1 and SMN2 reporter cells.  
The primer set’s efficiencies were determined based on a 5 point dilution curve 
for each.  The efficiencies were consistent between reporters and were 95%, 
95%, and 85% respectively.  Additionally, a melting point curve was performed 
for every reaction to confirm the product purity.  It is possible to determine the 
fold difference between total transcripts and exon 7 included transcripts and 
subsequently calculate the percent inclusion of exon 7.  The SMN1 reporter cells 
expressed 87% of transcripts containing exon 7 while SMN2 reporter cells 
produced 8% of transcripts including exon 7.   
 The increases of the luciferase activity in response to the HDAC inhibitors 
were validated by measuring the levels of both the total and exon 7 included 
mRNAs. To begin, we treated SMN2 B3 reporter cells with HDAC inhibitor 
compounds valproic acid, aclarubicin, and SAHA.  Three concentrations within 
the active range of each drug were added to the cells and mRNA was harvested 
and analyzed for changes in total and full length transcripts.   Comparison of the 
mRNA inductions between the two populations of mRNAs revealed potential 
mechanisms the drug use to increase SMN luciferase activity.   
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  As previously discussed, there are multiple mRNA based mechanisms 
that increase SMN protein levels.  Briefly, these include enhanced transcription of 
the SMN2 promoter, mRNA stabilization, and exon 7 splicing modification.  A 
transcriptional increase elevates both exon 7 included and skipped transcripts 
equally and should be reflected by comparable fold increases of total and exon 7 
included transcripts.  However, in practice we have observed that this is accurate 
at low to moderate increase of reporter transcription.   
Increased levels of mRNA induction and processing resulted in greater 
incidences of exon 7 skipping.  In this case it is possible that the increase of 
transcription and rate of transcription negatively affected the recognition of the 
weak splice sites of exon 7.  Recruitment and binding of splicing factors is 
mediated by RNA polymerase and associated proteins [116].  Increase of the 
rate of transcription in response to altered histone acetylation negatively impacts 
the inclusion of weak exons and promotes alternative splicing.  Moreover, the 
presence of nucleosomes and transcription pause sites within weak exons 
promote exonic inclusion [117].  Increased transcriptional rate can bypass this 
pause and concurrently cause exonic exclusion.  Therefore, it is possible that 
transcriptional compounds are directly effecting the population of splicing factors 
associating with the transcriptional complex at the SMN2 promoter or promoting 
exclusion of exon 7 via modification of the rate of the RNAP transcription. 
 The greatest increase of reporter mRNA was observed with SAHA 
treatment.  At the lowest concentration, 1.1 µM, the fold induction in total SMN 
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reporter mRNA and exon 7 included mRNA were comparable and likely reflect 
the HDAC inhibitor’s effect on promoter transcription.  At higher drug dosages 
there was nearly a 2 fold increase of exon 7 included transcript relative to total 
transcript (Figure 1.5 a).  This suggested that as the concentration of the HDAC 
inhibitor resulted in an enhanced effect on exon 7 splicing.  Presumably, this is 
the result of increased expression of exon 7 splicing enhancers such as hTra2β 
or SF2/ASF.  SAHA’s effects on transcriptional enhancement as well as reducing 
the percentage of exon 7 skipping resulted in nearly a 35 fold increase of full 
length transcript.  Similar results were observed following reporter treatment with 
valproic acid (Figure 1.5b).  However, the fold increases observed were nearly 3 
fold less than the levels obtained by 10.0 µM SAHA.  The results observed when 
SMN2-luciferase reporter cells were treated with aclarubicin differ from the other 
two HDAC inhibitors (Figure 1.5 c).  Splicing remains unchanged despite ample 
activation of the reporter mRNA in response to aclarubicin treatment.  Aclarubicin 
appears to be limited to transcriptional activation.  
The HDAC inhibitor LBH-589, a potent activator of SMN mRNA and 
protein levels has no effect on mRNA turnover [118].  This data in combination 
between the 99.9% identical mRNA transcripts, the reporter mRNA increases 
observed are likely to be the byproduct of enhanced transcription rather than 
mRNA stability. The behavior of the reporter mRNA in response to these 
compounds confirmed that the SMN2 reporter accurately reproduced SMN 
protein level increases consistent with published results.   
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Figure 1.5. Analysis of Changes of Reporter SMN mRNA Levels with Known 
SMN Activators.  qPCR analysis of SMN-luciferase reporter transcripts following 
24 hours HDAC inhibitor treatment (SAHA (A), Valproic Acid (B), and Aclarubicin 
(C)).  (A) SAHA treatment (1.1, 3.3, and 10.0 µM) results in a greater fold 
increase of exon 7 included transcript in relation to total reporter transcripts. (B) 
Valproic acid (0.27, 0.83, and 1.66 µM) increased reporter mRNA similar to 
SAHA, however was approximately 5 fold less potent.  (C) Aclarubicin (33, 100, 
and 300 µM) treatment increased both total reporter transcripts as well as exon 7 
included transcript.  In contrast to SAHA and valproic acid there was a 1.5 fold 
greater increase of total transcript relative to exon 7 included transcripts.  Data 
collected by author, figure compiled by Jonathan Cherry, Ph.D. 
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High Throughput Screen Target Validation 
 The SMN2-lucifease reporter cells line were used in numerous high 
throughput screens (HTS) at multiple collaborating sites to identify novel 
compounds that increased SMN protein levels.  Over 1 millions compounds were 
screened for SMN-luciferase activity.  A select number of compounds were 
identified based on assay activity, SMN2 selectivity over SMN1, and ease of 
medicinal chemistry. Activation was defined at 6 times the coefficient of variation 
for the entire screen, which corresponds to 60% activity over the DMSO controls.  
The compounds identified were LDN-66, -75, -76, -109, and analogs of NCGC-
533.  The LDN and NCGC compounds were identified in two separate screens 
and were chemically and structurally unique. 
Validation of LDN HTS Hits 
 Following the completion of the HTS, all active compounds were retested 
at multiple concentrations by Dr. Jonathan Cherry.  The compounds were 
screened for activity in the SMN1 and SMN2 reporters as well as an irrelevant 
cell line that expressed firefly luciferase under the control of the SV40 promoter 
(Figure 1.6a).  All four of the compounds LDN-66, - 75, -76, and -109 
preferentially activated the SMN2 reporter cell line in comparison to each of the  
other two cell types tested.  This was a critical step to determine that the 
compounds did not non-specifically increase transcription or luciferase activity.  
Activation of the SMN1 reporter does not necessarily indicate a poor SMA 
activating compound as the promoter regions are 99% identical.  However, one  
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Figure 1.6. Reporter assay validation.  (A) Comparison of luciferase 
activity for equivalent numbers of clonal SMN1-luc and SMN2-luc cells plated in 
96 well format and scored as relative light units (RLU).  Luciferase activity is 
nearly 60 times higher in the SMN1-luc reporter than the SMN2-luc reporter.  (B) 
Detection of SMN-luciferase fusion protein in HEK parent, SMN1-luc, and SMN2-
luc reporter cells.  Lysates were blotted for the fusion protein with an anti-
luciferase antibody and compared to α-tubulin as loading controls.  (C and E)  
SMN1-luc cells were treated for 24 hours with increasing amounts of SAHA.  The 
amount of SMN-luciferase fusion protein detected by anti-luciferase antibody (C) 
is similar to the % increase in luciferase activity over treatment with DMSO 
carrier in the same samples (E).  (D and F) SMN2-luc cells were treated for 24 
hours with increasing amounts of SAHA and sodium butyrate.  The increase in 
SMN-luciferase fusion (D) is compared to the % increase in luciferase activity (F) 
with both compounds.  Experiments were performed 3 times. Blots shown are 
representative. Data and figure courtesy of Jonathan Cherry, Ph.D. (submitted 
data) 
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objective of the HTS was to identify therapeutic compounds that were specific to 
SMN2 activation and thereby potentially minimizing off target or toxic side effects.  
HTS hits were screened in an SV40 luciferase cell line to filter out compounds 
that are potentially acting directly on the luciferase protein and increasing activity 
independent of SMN.   
Each of the four compounds had EC50 values in the low micromolar range 
while maintaining SMN2-luciferase activity of at least 169% (1.7 fold) (Figure 
1.6B).  Dr. Cherry measured the protein levels of the SMN-luciferase fusion 
protein in the B3 reporter cells following drug treatment, by Western Blot using an 
anti-luciferase antibody (Figure 1.6 c).  The fold change of SMN-luciferase were 
calculated in reference to DMSO controls and normalized to a β-actin well 
loading control Western blot.  The protein increases measured were comparable 
to the luciferase activity data. 
 The reporter was designed to identify compounds that increase SMN2 full 
length protein production without discrimination based on mechanism of action.  
Quantification of changes of reporter mRNA levels, or in exon 7 splicing, aids in 
the identification of the mechanism that the compounds may be exploiting.  
SMN2 reporter cells were treated with each of the LDN compounds for 24 hours 
prior to harvesting RNA and measuring luciferase activity.  Three concentrations 
of drug were chosen that fully encompass the active range of the compounds, 
3.3 µM, 10.0 µM, and 30.0 µM.   
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 All four compounds increased activity of the SMN2-luciferase reporter 
(Figure 1.7 – black bars).  LDN-76, -66, and -109 increased total and exon 7 
included mRNA (1.7 – white and gray bars respectively) with growing efficiency 
as the drug concentration was increased from 1.1 µM to 10.0 µM.   In each of 
these three cases the fold increase of total SMN reporter mRNA greater in 
comparison to full length transcripts.   Luciferase activity increases more closely 
mirrored the increases of exon 7 included rather than total transcripts.  With 
increased drug concentration there was a dose response from all mRNA species 
measured.  The pattern of mRNA increase resembled aclarubicin treatment 
(Figure 1.5C).  These data indicated that the most likely mechanism to increase 
reporter mRNA levels was transcriptional.   
 LDN-75 did not exhibit the same mRNA induction pattern observed with 
the other compounds.  LDN-75 failed to increase SMN-luciferase mRNA at the 
1.1 or 3.3 µM drug concentrations.  At the highest concentration, 10.0 µM, there 
was a 50% or 1.5 fold increase of both total and exon 7 included mRNA.  This 
data contradicted the other compounds where the increase of luciferase activity 
was directly comparable to full length mRNA induction.  In the case of LDN-75 
there was a 150% (2.5 fold) increase in reporter activity in the absence of 
elevated mRNA levels.  Western blot data in Figure 1.6C confirmed increased 
steady state levels  
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Figure 1.7.  SMN2-Luciferase Reporter Activity and mRNA Increases. 
Treatment of reporter cells for 24 hours with LDN-75, -76, -66, and -109 
increases reporter activity levels 100% (2 fold) over DMSO carrier treated cells.  
LDN-76,-66, and -109 increase total SMN-Luciferase mRNA levels (white bars) 
and exon 7 included mRNA (gray bars).  LDN-75 failed to increase reporter 
mRNA.  qPCR was used to calculate mRNA increases. GAPDH was used for 
normalization.  Data collected by author, figure compiled by Jonathan Cherry, 
Ph.D. 
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of the fusion protein.  The lack of mRNA induction suggests that the mechanism 
employed by LDN-75 is downstream of transcription. 
Dr. Cherry confirmed each of the LDN compounds increased SMN protein 
levels in SMA fibroblast cell lines.  Validation of the drugs activity on endogenous 
genes and protein eliminated the possibility that the effects observed were 
indirect and exclusive to the reporter cell line.  Secondary assays were 
performed; including gem count assays in primary fibroblasts to additionally 
confirm each of the compounds ability to increase SMN protein levels.  
Experiments testing the activity of the LDN compounds in a SMA mouse model 
for SMN protein levels as well as viability are currently pending. 
Validation of NCGC HTS Hits  
 In a separate HTS, 21 chemical compounds were selected as for further 
investigation.  These compounds were selected from a pool of approximately 
6000 compounds that were active in the SMN2 reporter assay.  Compounds 
were eliminated as viable drug targets based on known compound related cell 
viability data, an SMN1 reporter counter screen, as well as any evidence 
suggesting luciferase inhibition activity; Luciferase inhibitors can act to stabilize 
the protein at lower concentrations, thereby appearing to increase reporter 
activity in the primary HTS.  The entire set of 21 compounds was tested for the 
ability to increase endogenous protein in primary SMA fibroblasts.  From this final 
set of 21 compounds one compound was selected based on positive SMN 
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Western blot data as well as favorable chemical structure for medicinal chemistry 
and structure activity relationship experiments.   
 To begin chemical analogs were synthesized and tested for activity in the 
SMN2 reporter cell line.  Seven analogs were tested at four different 
concentrations, 0.111, 0.333, 1.100, and 3.300 µM by Dr. Cherry.  Each of the 
chemical analogs retained the ability to increase SMN-luciferase activity (Figure 
1.8).  The maximum percent increase of activity was equivalent with all 
compounds with the exception of NCGC-931.  The drug was more effective at 
lower concentrations with the EC50 in the low nM range.  This could indicate that 
medicinal chemistry on the chemical scaffold may have difficulty enhancing the 
increase of SMN protein levels.  However, further medicinal chemistry could 
increase drug potency, reducing the amount of compound necessary to increase 
SMN levels and possibly decreasing off target or toxic side effects. 
 Quantitative PCR was used to measure increases of reporter total and 
exon 7 included mRNA for each of the 7 chemical analogs in Figure 1.8.  Each of 
the chemical analogs failed to increase reporter mRNA.  Graphs for three of the 
NCGC compounds, NCGC-533, -564, and -931, are represented in Figure 1.9.  
The data for these three analogs are representative of all 7 compounds tested.  
Minor effects on both measured transcripts are consistent between each of the 
compounds.  The increases of luciferase activity observed are most likely due to 
post-transcriptional and mRNA processing events.  These data are most  
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Figure 1.8.  Measuring SMN2 reporter activity NCGC chemical analogs.  
SMN2-Luciferase reporter cells were treated with 7 NCGC compounds for 24 
hours prior to measuring firefly luciferase activity using Dual-Glo Luciferase 
assay system.  Signal was normalized to DMSO carrier treated reporter cells.  
Cells were treated with 4 different concentrations of compound, 0.111, 0.333, 
1.100, and 3.300 µM.  Each compound had comparable max activation of the 
reporter.  NCGC – 931 has the lowest EC50 in the low micromolar range.  Data 
and figure courtesy of Dr. Jonathan Cherry (submitted data).    
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Figure 1.9 Measuring SMN-Luciferase mRNA levels by qRT-PCR. NCGC-
531, -564, and -931 treatment on SMN2-Luciferase reporter cells for 24 hours.  
Levels of total SMN reporter transcripts and exon 7 included transcripts were 
measured by qRT-PCR and normalized to GAPDH.  Drug treatment failed to 
increase reporter mRNA despite luciferase activity increase (Figure 1.8).  qRT-
PCR was done for the other 4 NCGC compounds and mRNA levels were 
comparable to compounds -531, -564, and -931 shown.   
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comparable to the results obtained with compound LDN-75.  The quantitative 
PCR data reignited previous concerns that compounds may falsely activate the 
reporter by stabilizing the luciferase protein independent of SMN. 
 Therefore, new chemical analogs were developed taking into 
consideration the reporter data of Figure 1.8.  However, all subsequent analysis 
was performed exclusively in primary SMA fibroblasts to eliminate any luciferase 
related artifacts.  Two methods, Western blot and gem count assays, were used 
to measure the SMN protein levels in response to the NCGC compounds.  The 
primary fibroblasts selected for these experiments were the 3813 and 3814 cell 
lines [119].  The 3813 cell line was isolated from a type I SMA patient.  It contains 
two copies of the SMN2 gene and is homozygous null for SMN1.  The 3814 cell 
line was collected from a type I SMA carrier, with direct relationship to the 3813 
donor.  Initial characterization of these two cell lines reported a 10 fold difference 
in SMN protein levels [119].  With time and cell passage the protein levels in the 
3814 carrier cells are closer to 4 fold greater than the patient 3813 line.   
Three compounds, NCGC-8a, -8m, and -9a, were selected for Western 
blot and gem count experiments in 3813 cells.  Cells were treated at 5 
concentrations 0.037 µM,0 .111 µM, 0.333 µM, 1.000 µM, and 3.000 µM and 
compared to DMSO carrier treatment and carrier 3814 cells.  Approximately 100 
gems per 100 nuclei were detectable in carrier 3814 cells.  The intensity of 
immunofluorescent staining in these cells was intense and gems clearly 
distinguishable (Figure 1.10).  3813 cells contained 5 fold fewer gems SMN 
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signal was weak.  Treatment with 5 µM SAHA increased the number of gems 
detected per 100 nuclei; however the staining was still weak in comparison to 
carrier 3814 cells.  Compound NCGC-8a was ineffective at increasing the gem 
number in 3813 cells while NCGC-8m and -9a treatment resulted in nearly 2 fold 
increase in counts (Figure 1.11 B).  Quantification of Western blot data (Figure 
1.11 A) demonstrated remarkable similarity to SMN protein increases quantified 
by gem count assays. 
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Figure 1.10.  Immunofluorescence of endogenous SMN protein in primary 
SMA fibroblasts.  Immunohistochemistry staining of endogenous SMN protein 
(Green) with antibody 4F11. Primary SMA fibroblasts 3813 cells were treated for 
96 hours with 0.037, 0.111, 0.333, 1.000, and 3.000 µM compound (1.000 µM 
shown).  Genomic DNA was stained with Prolong Gold DAPI mounting media.  
Gems are labeled with green triangles. Primary SMA carrier fibroblasts, 3814, 
were used as reference. 
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Figure 1.11 Quantification of Gems in primary SMN fibroblasts.  Primary 
SMA fibroblasts 3813 cells were treated for 96 hours with 0.037, 0.111, 0.333, 
1.000, and 3.000 µM compound.  Quantification of protein increases determined 
by Western blot and gems counted per 100 nuclei.  Increases of protein 
observed were consistent between Western and gem count assays.  Western 
blot quantification was normalized to tubulin.  Fold increase and raw gem count 
data was shown for Western blog and immunofluoresence data respectively.  
Experiments were performed in triplicate. Panel A data collected and compiled by 
Jonathan Cherry, Ph.D. 
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Discussion and Future Directions 
 
 There is a significant effort to identify and develop novel therapies for 
spinal muscular atrophy.  The compounds that have been tested in clinical trials 
have produced results with little or no significant survival benefit to SMA patients.  
Previous HTS screening tools focused on compounds that targeted SMN2 
transcription or exon 7 splicing.  Dr. Cherry developed a novel luciferase based 
reporter cell lines that included the minimal promoter driving SMN exon 1-5 
cDNA fused to an exon 7 splicing cassette.  The final product is a full length SMN 
protein fused to luciferase only when exon 7 is included.  The advantage of this 
system is that it maintains the potential to identify therapies that increase SMN 
proteins at various mechanistic levels from gene to protein. 
 This body of work characterized the episomal reporter mRNAs as well as 
assisted in the identification, validation, and development of new SMN activating 
chemical compounds.  Cell lines stably maintaining episomal SMN1 and SMN2 
reporter constructs were found to produce exon 7 included and excluded 
transcripts in ratios that agreed with published reports.  Additionally, the 
increases of reporter transcripts in response to known SMN activating 
compounds, SAHA, valproic acid, and aclarubicin were consistent with expected 
results.   
 In two separate high throughput screens 5 compounds were identified and 
selected for further study as potential SMN activating compounds.  Quantitative 
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PCR revealed that three compounds LDN-76, -66, and -109 increased SMN RNA 
that fits the pattern of transcriptional upregulation.  LDN-75 and the NCGC 
analogs failed to increase SMN transcripts.  The effect on SMN protein was 
confirmed in SMN primary fibroblasts.  Therefore, any effect these compounds 
have on steady state SMN protein levels was independent of any mRNA based 
mechanism. 
 LDN-75 and the NCGC compounds likely act to stabilize the SMN protein.  
An interaction between SMN and ubiquitin carboxyl-terminal hydrolase L1 
(UBCH1) is at least partially responsible for regulating SMN protein levels.  
Overexpression of UBCH1 results in decreased steady state levels of SMN 
where chemical inhibition of the protein increased SMN protein and gem 
numbers.  Therefore, it is possible that LDN-75 and the NCGC analogs are 
functioning in a similar pathway, inhibiting the proteosome degradation of SMN.  
The HDAC inhibitor LBH-589 has been demonstrated to act directly on protein 
stability in addition to transcriptional and splicing effects.  LBH-589 lowers levels 
of SMN poly-ubiquitination and thereby reduced the degradation and protein 
turnover.  The increase of SMN protein is comparable to levels achieved by 
proteosomal inhibition by MG132 [118].  The luciferase reporter is activated 
between 2 and 3 fold with LDN-75 and the NCGC analogs.  This is nearly 
identical to data obtained following MG-132 treatment.  However, there is no 
direct evidence that LDN-75 or the NCGC analogs function in a similar manner.   
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 Identification of the molecular targets of these compounds would 
significantly benefit their development towards effective SMA therapies.  
Knowledge of the drug target’s protein structure can reveal potential binding sites 
and further drive medicinal chemistry to increase drug potency, minimize side 
effects, and reduce binding to off target proteins.  Additionally, discovery of a 
novel protein in SMA biology could foster investigations that may give insight into 
disease progression and the susceptibility of motor neurons to low SMN levels.  
The medicinal chemistry already done and tested in high throughput format has 
mapped sites on the base chemical structure that can be changes without 
sacrificing SMN induction activity.  At these sites it is possible to covalently link a 
moiety such as biotin to enable precipitation of the compound and any bound 
proteins from cell lysates.  Multidimensional protein identification technology 
(MudPIT) mass spectrometry or conventional SDS-PAGE band excision followed 
by matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry could be used to indentify proteins precipitated from the biotin-drug 
treated lysates.  Without target identification it is still possible to delve deeper into 
the mechanisms used to increase SMN protein.  In particular, LDN-75 and the 
NCGC analog’s pathway to elevated protein levels are largely unknown.  Further 
experiments measuring protein half-life and SMN ubiquitination in response to 
drug treatment would determine if the compounds target SMN protein 
degradation.  
74 
 
Moving forward the compounds characterized in this set of data should be 
tested in mouse models of SMA.  Additionally, a concerted effort must be made 
to identify the drug targets as well as cellular pathways being used to increase 
SMN protein.  However, the groundwork laid out in these experiments 
demonstrates that the episomal cell lines are valuable tools for future drug 
screening and validation studies.  The reporter mimics the behavior of the 
endogenous genes more completely than any other system to date.  The whole 
protein fusion protein strategy has identified novel compounds that show extreme 
promise as potential SMA therapeutic compounds. 
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Chapter II: 
Silencing of Individual HDAC Protein Differentially Increases  
SMN-Luciferase 
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Histone Deacetylase Inhibitors 
 
 Histone Deacetylases are a family of proteins that primarily regulate the 
removal of acetyl (-CHCO3) groups from lysines on histone proteins in a Zn+ 
dependent mechanism [120].  HDACs work opposing histone acetyl-transferase 
proteins to determine the balance of histone acetylation.  The acetylation state of 
histone tails regulates the confirmation of chromatin and subsequently regulates 
the access of transcriptional machinery to the DNA [120, 121].  Briefly, 
hypoacetylated histones condense chromatin and down regulate transcription 
while hyperacetylation relaxes the chromatin structure and increases 
transcription (Figure 2.1).  DNA methylation as well as histone tail methylation in 
cooperation with acetylation modulate transcriptional silencing [122].  SMN2 is 
known to be methylated at CpG islands and the level of methylation correlates to 
the transcriptional activity of the promoter.  Treatment with HDAC inhibitors is 
capable of increasing SMN2 transcriptional products independent of promoter 
methylation [123].  HDAC proteins are currently categorized into four classes 
primarily based on homology to yeast deacetylase proteins [124].  Class I 
(HDACS 1, 2, 3, and 8) HDACs are similar to the Saccharomyces cerevisiae 
transcriptional regulator RPD3.  Class II HDACs (HDACS 4, 5, 6, 7, 9, and 10) 
are more closely related to yeast HDA1 [124].  Class III HDAC proteins are 
homologous to yeast SIR1 and are Nicotinamide adenine dinucleotide (NAD+) 
dependent.  The final class of HDAC contains only one protein, HDAC11[125].   
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Figure 2.1 Schematic Summary of Histone Acetylation.  Cartoon diagram 
showing effect of histone tail acetylation on chromatin confirmation (acetylation – 
stars).  Acetylated histones relax chromatin allowing enhanced transcription 
factor access to promoter and results in increased mRNA production.  Removal 
of acetyl groups from histone tails condenses chromatin and is associated with 
increased CpG island methylation (-Me) resulting in gene silencing. 
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There is insufficient sequence homology or functional data to categorize 
HDAC11 in any of the other three classes. 
 Class I HDACs are almost exclusively nuclear and fairly uniformly 
expressed in all tissue types, with only HDAC3 occasionally shuttling to the 
cytoplasm via a nuclear export signal [126].  Regulation of the class I HDAC is 
largely controlled by secondary proteins affecting deacetylase activity or 
recruitment to the genome [127, 128].  Class II HDACs localization is dependent 
on cellular signal and can be either cytoplasmic or nuclear.  Class II expression 
profiles indicate these proteins are more varied between individual tissues.  
HDAC 5, 6, 7, and 10 distribution is as uniform as Class I, while HDACs 4, 8, and 
9 are elevated in tumor tissue and found at variable levels in other tissues.  Class 
II HDAC regulation is achieved by signal induced shutting out of the nucleus, 
removing the proximity of the HDAC from the histone.   
 The SMN promoter is non-remarkable relative to histone acetylation.  The 
promoter region surrounding the transcriptional start site is populated by H3 and 
H4 histones and is conserved between mouse and human samples.  Only 
HDAC1 and HDAC2 have been reported to be bound to the SMN promoter [129].  
Both proteins were confirmed to also be bound to the SMN2-luciferase reporter 
promoter (Figure 2.2).  Consequently, the episomal reporter is seemingly under 
the regulation of the same protein as the endogenous gene.   SMN binds HDAC2  
and Sin3A, a HDAC1/2 co-repressor protein.  It is unclear what impact these 
associations have on SMN expression or SMA biology. 
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Figure 2.2. Chromosome Immunoprecipitation of HDACs at the SMN2-
luciferase Reporter Promoter.  The SMN promoter was isolated from untreated 
HEK293T SMN2-luciferase reporter cells using chromosome 
immunoprecipitation.   Irrelevant Rabbit IgG and anti-RNA Polymerase CTD 
antibodies were used for negative and positive controls respectively.  The 
reporter promoter was successfully immunoprecipiated, consistent with published 
endogenous reporter data.  Both HDAC3 and HDAC6 do not appear to bind the 
SMN2-luciferase reporter in the amplified region. 
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 HDAC inhibition is thought to increase expression and deacetylate non 
histone proteins that regulate apoptotic cell death.  HDAC inhibitors act by 
blocking access to the Zn2+ ion from the catalytic core thereby inhibiting 
deacetylase activity. There are multiple clinical trials currently ongoing 
investigating the role of HDAC inhibition in treating malignancies and solid 
tumors [130, 131].  The first new generation HDAC inhibitor to be Food and Drug 
Administration (FDA) approved for the treatment of cutaneous T-cell lymphoma 
was suberoylanilide hydroxamic acid (SAHA / Vorinostat) [132].     
Phenylbutyrate (PB) and valproic acid (VPA) were initially tested to 
increase SMN levels in tissue culture and mouse models because of in place 
safety information from FDA approved uses [115, 133, 134].  Both compounds 
showed 2 to 4 fold increases in SMN mRNA or protein in SMA patient derived 
cell lines.  The success of in vitro tests of these compounds prompted clinical 
trials with SMA patients to be opened.  PB was observed to increase SMN levels 
in blood leukocytes of patients and carriers and displayed some functional 
benefit.  One suspected failing of PB is the short half life of approximately 1 hour.  
VPA, which has a much longer half life of approximately 8 hours, had variable 
results in multiple clinical trials.  Between studies, and even patients within 
individual trials, the response to VPA was highly variable [95].  Some patients 
increased SMN protein levels in leukocytes and experienced some strength 
benefits.  Increased SMN2 copy number appears to proportionally increase the 
benefits of VPA administration.  As SMN2 is the target of transcriptional increase 
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with HDAC inhibitors this result is not surprising, however does provide another 
variable in the search for a viable SMA therapy. 
Newer generation HDAC inhibitors are currently being tested for ability to 
increase SMN protein levels in tissue culture and mouse models.  LBH589 
(panobinostat), M344, trichostatin-A (TSA), and SAHA have all shown a capacity 
to induce higher levels of SMN protein [114, 118, 135-137].  In the case of M344 
and LBH589 the fold change of SMN protein in SMA patient cell lines is between 
7 and 10 fold greater than control samples.  This change is far greater than the 
levels achieved using PB or VPA in previous studies.  However, it is difficult to 
compare fold changes as cell lines and treatment courses vary between studies.  
Administration of SAHA and TSA to severe SMA mouse model showed 
increased strength in addition to increases in motor neuron number and size of 
neuromuscular junctions.  Most importantly, drug treatment increased survival by 
approximately 30 percent when compared to untreated littermates.  
While there are many promising aspects of HDAC inhibitors as SMA 
therapy, there are still many detracting features associated with this class of 
compounds.  HDAC inhibitor trails for cancer therapy have even suggested that 
some patients may be immune to the beneficial effects of this class of 
compounds.  An ideal SMA therapeutic compound will effective in all patients 
regardless of age, weight, and genetics.  It is important to identify possible 
markers that will determine a particular patient’s potential response to any given 
treatment.  Secondly, there is an intrinsic toxicity associated with HDAC inhibitor 
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compounds.  The population of genes that are modified following HDAC inhibition 
is diverse and can also have broad and unpredictable effects within the cell and 
whole system.  Increased expression of SMN in a beneficial outcome of this 
process, however the extent of other changes is largely unknown.  Despite these 
challenges, HDAC inhibitor are still among some of the most potent SMA 
therapies and research must continue to understand the effects these 
compounds have on SMN expression. 
In this study we sought to elucidate the role that individual HDAC proteins 
have on the regulation of SMN expression.  We specifically targeted HDACs 1-8 
by the expression of short hairpin RNAs (shRNAs) and measured SMN protein 
levels using a SMN2 luciferase reporter cell line.  We then determined the effects 
of reduced HDAC levels on SMN2 transcription, exon 7 inclusion, and mRNA 
levels of SMN splicing modulators hTra2β, hnRNP A1, and SF2/ASF.  Silencing 
of individual HDAC mRNA was sufficient to increase the amount of SMN reporter 
transcripts, and increase reporter activity.  Changes in total and full length mRNA 
were differentially affected by the individual HDAC proteins silenced.  While 
enhancing the basic understanding of SMA biology and SMN2 gene expression 
regulation, these data will also identify potential drug targets that may have less 
toxic properties than pan-HDACi while maintaining sufficient SMN protein 
induction. 
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Materials and Methods 
 
Tissue Culture 
 Cells were incubated at 37 C with 5% CO2.  HEK-293 reporter SMN2 -
luciferase cells were grown in D-MEM (Gibco, #11995) with 10% fetal bovine 
serum (Sigma) and 1x Pen-Strep (Gibco, #15140) with 200 ug/mL hygromycin B 
(Invitrogen, #10687-010).  Primary human SMA patient fibroblasts, 3813, were 
grown in D-MEM with 15% fetal bovine serum and 1x Pen-Strep. 
shRNA Vectors and Transfection 
 All shRNA vectors were obtained from openbiosystems via the UMass 
Medical School RNAi Core Facility.  All shRNAs were in the pGIPZ vector also 
expressing GFP under the CMV promoter.  HDAC1 (V2LHS_61809, 
V3LHS_344564), HDAC2 (V2LHS_132136, V3LHS_382880), HDAC3 
(V2LHS_53152, V3LHS_380875), HDAC4 (V2LHS_71327, V3LHS_340831), 
HDAC5 (V2LHS_68644, V3LHS_321382), HDAC6 (V2LHS_71188, 
V3LHS_330045), HDAC7 (V2LHS_96401, V3LHS_351666), and HDAC8 
(V3LHS_355330, V3LHS_355335), pGIPZ Non-Silencing Control.  1 ug shRNAs 
were transfected into 200,000 SMN2-luciferase reporter cells in a 12 well tissue 
culture treated dish using Lipofectamine 2000 (Invitrogen) at a 1:4 DNA: 
Lipofectamine 2000 ratio.   
Luciferase Assays 
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 Luciferase was measured 48 hours post transfection by harvesting cells 
with 1X trypsin (Gibco #15050-065) followed by trypsin inhibitor (Invitrogen 
#17075-029) followed by PBS collection and centrifugation.  10% of cells by 
volume were equally distributed into 3 wells of a white tissue culture 96 well 
plate.  The remaining 90% of cells were saved for RNA quantification.  Promega 
Dual-glo luciferase assay system was used to determine SMN-luciferase activity 
as done previously (Cherry).  MS-275 was purchased through SelleckChem 
(#W12277).   
Primary Cell Assays 
 Lentiviruses expressing HDAC shRNA clones were obtained from the 
UMass Medical School RNAi Core Facility.  Lentivirus was added to 250,000 
primary 3813 cells, plated in a 10 cm tissue culture dish, at a multiplicity of 
infection (MOI) of 10 in the presence of polybrene.  Growth medium containing 
10% FBS and 1 % p/s  was replaced 24 hours following infection and allowed to 
grow an additional 48 hours before harvesting RNA by Trizol preparation.  
Infection was confirmed prior to the media change by way of visual confirmation 
of GFP marker expression.  Reduced mRNA steady state levels were confirmed 
by semiquantitative endpoint PCR with the same primer sets and conditions as 
the reporter cell assays.   
PCR and qRT-PCR 
RNA was isolated from cells using Trizol Reagent (Invitrogen, #15596-
026).  cDNA was generated using the Improm-II Reverse Transcription System 
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(Promega, #A3801).  The primer sets used are the same as described in chapter 
1. Briefly, Primer sequences: Exon5/Xho-forward: catttccttctggaccactcgag, 
Exon6-forward: gcccaaatctgctccatggaac, Luciferase-reverse: 
atagcttctgccaaccgaacgg, Exon7-reverse: taaggaatgtgagcaccttccttc, Exon8-
reverse: gatctgtctgatcgtttctttagtgg, GAPDH-reverse (G3A): tccaccaccctgttgctgta, 
GAPDH-forward (G3S): accacagtccatgccatcac. 
 The primer pairs to determine HDAC mRNA levels and splicing factor 
mRNA changes were as follows (forward, reverse), HDAC1 
(tcggggctggcaaaggcaag, agaccaccgcactaggctgga), HDAC2 
(tgctactactacgacggtgatattgga, tcggcagtggctttatggggc), HDAC3 
(gccccatcgcctggcattga, tcctcggagtggaagcggca), HDAC4 (cggagaacggtatcgcgccc, 
ggcaggcccagcgtgatgtt), HDAC5 (tgaactctcccaacgagtcgga, 
gggcatggctcttggcagca), HDAC6 (acccacctgctgatgggcct, gcaggggtggtgggtctcca), 
HDAC7 (ccgttcgccttgccgacagt, gtgtgggggctccccaggat). HDAC8 
(cagtgggcagtcgctggtcc, ggaaggtggccatctcctcca), hTra2β 
(cacatcgaccggcgacagca, ccccgatccgtgagcacttcc), SF2/ASF 
(ttagatctcatgagggagaaactgcc, ggcttctgctacgactacggc), hnRNP A1 
(agggcgaaggtaggctggca, gcttcctcagctgttcgggct). 
qPCR was performed as described in the protocol for iQ SybrGreen 
Supermix (BioRad, #170-8882) in an Eppendorf Mastercycler ep Realplex 4 real-
time PCR machine.  Reactions were incubated for a 10 minute 94 oC hot start 
followed by 45 cycles of the following: 94 oC for 45 second, 60 oC for 15 seconds, 
89 
 
72 oC for 45 seconds.  The Pfaffl method was used to determine the change in 
transcript levels relative to the DMSO or non-silencing shRNA controls and 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).   
Chromosome Immunoprecipitation (ChIP) 
 Formaldehyde was added directly to tissue culture media to a final 
concentration of 1%.  Cells were allowed to incubate at 37o C for 10 minutes.  
Cells were washed with 1X PBS and collected in 1mL PBS.  ChIP protocol was 
performed as described (Upstate Cell Signaling) using anti-acetyl histone H3 
(Upstate # 06-599) and RNA Polymerase II CTD (abcam #ab5095). Antibodies 
were bound and washed using Protein A Dynabeads (Invitrogen # 10002D) 
Following reverse crosslinking and Proteinase K digestion, DNA was purified 
using Qiagen Quick PCR Clean-Up Kit.  qPCR was performed as above.  
Percent input bound was calculated based on a 5 point standard dilution curve of 
each relative input.  Primer Sequences: Forward (Promoter): 
ggccaccgtactgttccgc, Reverse (Exon 2):  ccaaatgtcagaatcatcgctctgg. 
Statistical Analysis 
 An unpaired two-tailed t-test was selected to compare the means of 
treated and untreated samples.  Treated and untreated samples were handled 
identically and therefore any variations can be consider equal.  Statistical 
significance is determined by a p-value less than 0.05, or less than 5% 
confidence that the difference between the two samples are sue to random 
variance. 
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Results 
 
SMN2-Luciferase reporter responds to HDAC inhibitors 
 We theorized that individual HDAC proteins have distinct contributions to 
the regulation of SMN expression.  We wished to characterize how a class I 
specific HDAC inhibitor would respond in our reporter cell system [138].  We 
compared the selective HDAC inhibitor MS-275 (Entinostat) with two pan-HDAC 
inhibitors, SAHA and M344. Both have been shown to increase SMN levels.  MS-
275 has previously been tested for activation of SMN levels, however no 
significant induction was observed in primary SMA patient fibroblasts [139].  The 
reporter used in this study is expressed from the 3.4 kB SMN2 promoter followed 
by exons 1 through 5 cDNA linked to a SMN2-luciferase splicing cassette ([111]).  
The luciferase protein is only properly translated when SMN exon 7 is included in 
the processed mRNA.  When exon 7 is excluded, the exon 6-8 junction shifts the 
reading frame and translation is prematurely terminated early in the luciferase 
gene (Figure 1.1)  Each of these drugs were tested at four concentrations, .37 
µM, 1.10 µM, 3.30 µM and 10.0 µM.  Both SAHA and M344 increased SMN 
luciferase levels up to 10 fold.  MS-275 activity was less active, only achieving 4 
fold increase of the fusion protein (Figure 2.2A).  Activation of the reporter by the 
class I specific drug MS-275 implied that inhibition of a subset of HDAC proteins 
is sufficient to increase SMN protein levels.     
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Analysis of mRNA changes in the SMN2-luciferase reporter following HDACi 
treatment 
 To further elucidate the mechanism that the individual HDAC inhibitors 
use to increase the SMN expression, we quantified changes in the reporter 
mRNA.  We used primers specific to the SMN-luciferase splicing cassette 
transcript to measure the increase of both total transcript and exon 7 included 
mRNA alone.  The primers used to measure the total levels of reporter mRNA 
span exon 6 through luciferase.  Therefore, both exon 7 included and exon 7 
skipped transcripts will be measured.  Exon 7 included transcripts use a primer 
set from exon 6 through exon 7.  Increases of total reporter mRNA is indicative of 
an upregulation of transcription at the SMN2 promoter.  An increase of exon 7 
included reporter mRNA greater than that observed for total reporter mRNA can 
be considered a shift in the splicing of exon 7.  This can only be inferred because 
changes in splicing of the reporter mRNA should not affect the amount of mRNA 
present, only the ratio of total reporter mRNA to exon 7 excluded transcripts.   
SAHA and M344 induced nearly identical increases in the reporter mRNA.  Both 
total and exon 7 included mRNA were increased following drug treatment.  As 
the drug concentration increased there was a greater difference between exon 7 
included transcripts and total mRNA.  (Figure 2.2B)  This suggests that at lower  
concentrations the pan-HDAC inhibitors may directly affect the acetylation state 
of the histones populating the SMN2 reporter promoter.  With the increase of 
drug, there is also an increased effect on relevant targets potentially including the 
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Figure 2.3. HDAC inhibition increases SMN-Luciferase Activity and 
Reporter mRNA Levels.  (A) HDAC inhibitors increase SMN-luciferase activity 
levels.  SMN2 reporter cells were treated for 24 hours with 0.37, 1.10, 3.30, and 
10.0 µM SAHA, M344, and MS-275.  Pan-HDAC inhibitors increased reporter 
activity nearly 10 fold at the highest concentration.  Class I specific HDAC 
inhibitor increase reporter activity 4 fold.  (B) qRT-PCR was used to measure 
increases of SMN-luciferase mRNA following treatment with HDAC inhibitors.  
Fold increase of mRNA was normalized to GAPDH.  Pan-HDAC inhibitors SAHA 
and M344 increase exon 7 reporter mRNA a greater fold than total mRNA.  MS-
275 appears to increase total SMN-luciferase mRNA preferentially. Two tailed t-
test was used to calculate statistical significance.  P-values – (**** - < 0.0001, *** 
- 0.0001 - 0.001, ** - 0.0011 – 0.01, * - 0.011-.05).  Error bars are SEM. 
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splicing factors which in turn modifies SMN2 splicing.  The reporter mRNA 
analysis agrees with previously published reporter stating that these drugs not 
only increase the transcription activity at the SMN2 promoter but also increase 
exon 7 inclusion.     
Analysis of mRNA changes following MS-275 treatment revealed a 
different profile than what was observed with the pan-inhibitors.  Class I specific 
HDAC inhibition increased both total and exon 7 included mRNA.  However, the 
fold increases of the total transcript exceeded that of exon 7 included (Figure 
2.2B).  Therefore, we propose that MS-275 maintains the ability to positively 
affect SMN2 transcription, but is not capable of reducing exon 7 skipping.  
Silencing of HDAC proteins increases SMN reporter protein levels 
 Analysis of mRNA increases with MS-275 and pan-HDAC inhibitors SAHA 
and M334 revealed key mechanistic differences.  Therefore, we targeted 
individual HDAC proteins to clarify the possible role that each plays in regulating 
SMN levels.  Due to the close homology of all of the HDAC proteins, we targeted 
a sampling of both class I and class II HDAC proteins using an expression based 
shRNA construct.  This method allowed for direct and specific inhibition of a 
single HDAC protein, avoiding cross inhibition between HDACs possible with the 
use of chemical inhibitors.  We transfected the SMN2 reporter cells with shRNAs 
specific for HDAC1-8 and assayed for changes in the SMN-luciferase activity 
levels.  We confirmed using semi-quantitative endpoint-PCR HDAC mRNA 
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knockdown (Figure 2.4).  Reduced levels of the class I HDAC1, 2, 3, and 8, all 
increased SMN-luciferase reporter by at least 1.5 fold (Figure 2.5A).    
 Knockdown of the individual class II HDACs 4, 6, and 7 resulted in an 
increase of reporter activity, with HDAC6 showing the highest induction.  HDAC5 
silencing resulted in a small increase in luciferase activity (p-value - 0.0222).  
While this does indicate with high probability that the increase of reporter activity 
was not random, the same levels of confidence (p-value < 0.0001) reached by 
other HDAC knockdown was not achieved.  Therefore, at this point of 
investigation the direct role of HDAC5 on SMN2 expression may be significantly 
muted relative to the other HDAC proteins. The level of reporter activation 
following shRNA transfection was tempered in comparison to the fold changes 
observed using HDAC inhibitors.  However, this could be expected as we 
measured only the contribution of partial decrease of an individual HDAC protein 
relative to broader inhibition of HDACs by chemical inhibitors.   
Analysis of mRNA changes in the SMN2-luciferase reporter following shRNA 
treatment 
We hypothesized that the differences in mRNA expression observed in the 
presence of class specific HDAC inhibitors would also be observed when 
individual HDAC proteins were specifically targeted.  The increased mRNA 
expression profiles for in each class of protein mirrored the results from the drug 
assays.  Knockdown of the class I HDAC proteins, HDAC1, 2, 3, and 8, 
increased total mRNA more than exon 7 included transcript (Figure 2.5B). This is  
96 
 
 
 
 
 
 
Figure 2.4. Endpoint RT-PCR Confirms Silencing of Individual HDAC 
mRNAs. Semi-quantitative PCR of individual HDAC proteins transcripts with 
non-silencing or specific shRNA treatment.  RNA was harvested 48 hours post-
transfection of 1 ug of shRNA construct.  Percent knockdown of mRNA was 
quantified using ImageJ to analyze pixel intensity and density.  Signal was 
normalized to GAPDH RT-PCR reactions.  Quantification of signal loss is 
presented to the right of gel data.  Error bars are SEM. 
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Figure 2.5. shRNA Silencing of Individual HDACs Increase SMN-Luciferase 
Activity and mRNA.  (A) HDAC shRNAs increase SMN-luciferase activity levels.  
SMN2 reporter cells were treated for 48 hours with shRNA.  HDAC2 silencing 
increased luciferase activity the greatest at nearly 2 fold.  HDAC5 knockdown 
appears to have no effect on luciferase activity (B) qRT-PCR was used to 
measure increases of SMN-luciferase mRNA following treatment with HDAC 
shRNA.  Fold increase of mRNA was normalized to GAPDH.  Class I HDAC 
proteins shRNA treatment increased total reporter mRNA greater than exon 7 
included mRNA indicating possible transcriptional activation.  HDAC4 and 7 also 
appear to increase reporter transcription, while HDAC5 and HDAC6 increase 
exon 7 inclusion in addition to enhancing transcription.  Two tailed t-test was 
used to calculate statistical significance.  P-values – (**** - < 0.0001, *** - 0.0001 
- 0.001, ** - 0.0011 – 0.01, * - 0.011-.05) Error bars are SEM. 
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consistent with the results from the MS-275 and supports a transcriptional 
regulation role for these proteins.  Analysis of the mRNA increases following 
shRNA transfection of the class II HDAC protein revealed a more diverse set of 
profiles.  Silencing of HDACs 4 and 7 resulted in a pattern consistent with 
transcriptional regulation, while HDAC5 and 6 shRNA treatment increased exon 
7 included mRNA more than total reporter mRNA.  This suggests that these two 
proteins contribute to the splicing regulation of SMN exon 7 (Figure 2.5B).  In 
comparison to the other proteins tested it is with the least amount of confidence 
(p-value 0.0107) that HDAC6 has significant effect on SMN2 transcription.  This 
may be highly relevant due to HDAC6’s highly documented role in the cytoplasm.   
HDAC5 shRNA treatment resulted in an abundant increase of SMN-luciferase 
mRNA transcripts without any noticeable impact on SMN-luciferase activity 
(Figure 2.5A).  The known function of HDAC5 does not indicate an explanation 
for this observation.  It is possible that silencing of HDAC5 increased reporter 
mRNA and promoted inclusion of exon 7, but concurrently inhibited translation or 
caused a premature termination or translational frame shift.  We next attempted 
to target HDAC proteins in the primary SMA cell line 3813 and measure 
endogenous SMN2 transcripts.  We infected 3813 cells with lentivirus expressing 
the same shRNA used transiently on reporter cells.  We confirmed knockdown of 
HDAC mRNA using semi-quantitative PCR.  Results indicated there were no 
increases of endogenous SMN2 transcripts that would not have also been 
present in an identical population (p-values > 0.1, data not shown).   
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Figure 2.6. Quantitative PCR of Endogenous Splicing Factors In Response 
to HDAC Inhibitor Treatment In SMN2-Luciferase Reporter Cells.  SMN2-
luciferase reporter cells were treated with 4 concentrations of HDAC inhibitors 
SAHA, M344, and MS-275.  mRNA levels of splicing factors hTra2β (white bars), 
hnRNPA1 (gray bars), and SF2/ASF (dark gray bars).  qRT-PCR was used to 
measure fold changes in transcript levels relative to DMSO carrier treated cells.  
GAPDH was used for normalization.  Two tailed t-test was used to calculate 
statistical significance.  P-values – (**** - < 0.0001, *** - 0.0001 - 0.001, ** - 
0.0011 – 0.01, * - 0.011-.05). Error bars are SEM. 
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Analysis of changes of endogenous splicing factor mRNAs 
 Increases in mRNA and protein levels of the known SMN splicing factors 
Tra2β, hnRNAP A1, and SF2/ASF have been reported to promote inclusion of 
SMN exon 7 in SMN2 transcripts.  To investigate whether these same 
mechanisms are operative in the reporter cells; we measured the mRNA levels of 
these splicing factors following drug or shRNA treatment.  hnRNP A1, an 
inhibitory splicing factor, was decreased following treatment with each of the 
three chemical HDAC inhibitors tested.  At 10.0 µM M344, hnRNP A1 transcripts 
were elevated relative to the lower levels observed at lower drug concentrations.  
hTra2β transcript levels were increased in response to both M344 and SAHA, 
with no effect in response to MS-275 treatment.  SF2/ASF was only significantly 
increased when reporter cells were treated with M344 (Figure 2.6).  This is in 
agreement with data in Figure 2.3 showing a more potent response in fold 
increase of exon 7 included mRNA in response to M344 over that of SAHA at the 
same concentration.    
Analysis of these same transcripts following shRNA treatments did not 
reveal any direct pattern associated with the mechanisms determined by SMN 
transcripts analysis.  shRNAs specific to HDAC1 or HDAC2, both suspected 
transcriptional regulators, show nearly identical effects on total and exon 7 
included SMN reporter mRNAs in Figure 2; however, in this experiment low 
levels of HDAC1 significantly increased hTra2β and SF2/ASF (p-values 0.0425, 
< 0.0001 respectively), while HDAC2 shRNA treatment was inactive (p-values 
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0.66, 0.76 respectively) (Figure 2.7).  Additionally, silencing of HDAC5 and 6 
similarly increase the levels of endogenous splicing factors as HDAC1; yet 
analysis of the SMN reporter transcripts argues the mechanism of SMN increase 
differs between the two HDACs.  Therefore, there is no direct correlation of these 
splicing factor mRNA levels to the affect on SMN reporter mRNA.  Modulation of 
SMN splicing is not exclusive to these three proteins measured.  The entirety of 
proteins required to promote exon 7 inclusion may not be sufficiently modified by 
single HDAC knockdown.  Hence, the reason why more potent pan-HDAC 
inhibitors may be required to directly modify SMN exon 7 splicing.   
Quantification of Acetyl-Histone H3 and RNA Polymerase II at the reporter 
promoter 
  We measured the amount of acetyl-histone H3 and RNA Polymerase II 
present at the reporter promoter to determine the effects shRNA or HDAC 
inhibitor treatment imparts on transcriptional modulators.  Acetyl-H3 has been 
reported to populate the SMN2 promoter surrounding the transcriptional start site 
[129].  In the same study HDACi treatment increased the bound levels of acetyl-
H3 occupying the promoter of primary SMA fibroblasts.  We treated reporter cells 
with a single dosage of each HDACi as well as each shRNA.  We performed 
chromosome immunoprecipitation using an acetyl-histone H3 and RNAPII  
antibodies and subsequent qPCR to measure the percent of input DNA bound by 
acetyl-H3 and RNAP. 
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Figure 2.7. Quantitative PCR of Endogenous Splicing Factors In Response 
to HDAC shRNA Treatment In SMN2-Luciferase Reporter Cells.  SMN2-
luciferase reporter cells were treated with HDAC specific shRNA.  mRNA levels 
of splicing factors hTra2β (white bars), hnRNPA1 (gray bars), and SF2/ASF (dark 
gray bars).  qRT-PCR was used to measure fold changes in transcript levels 
relative to a non-silencing shRNA control.  GAPDH was used for normalization.  
Two tailed t-test was used to calculate statistical significance.  P-values – (**** - < 
0.0001, *** - 0.0001 - 0.001, ** - 0.0011 – 0.01, * - 0.011-.05). Error bars are 
SEM. 
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Figure 2.8. Quantitative Chromosome Immunoprecipitation of the SMN2-
Luciferase Promoter. The SMN promoter was isolated from HDAC inhibitor (A) 
or HDAC shRNA treated HEK293T SMN2-luciferase reporter cells using 
chromosome immunoprecipitation.   Irrelevant Rabbit IgG was used for a 
negative control.  qPCR was used to accurate determine the percent of input 
DNA bound by anti-acetyl-H3 and anti-RNA Polymerase CTD antibodies.  Two 
tailed t-test was used to calculate statistical significance relative to DMSO or non-
silencing shRNA controls.  P-values – (**** - < 0.0001, *** - 0.0001 - 0.001, ** - 
0.0011 – 0.01, * - 0.011-.05).  Error bars are SEM. 
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Treatment of the cells with each of the three HDAC inhibitors resulted in 
increases of approximately 1.5 fold in RNAP ChIP at the reporter promoter 
(Figure 2.8A).  High deviations between experiments revealed that only MS-275 
and M344 treatment increased RNAP presence at the reporter promoter greater 
than random chance (p-values 0.0046 and 0.0257 respectively).  All increases 
observed with Acetyl-Histone H3 ChIP were insignificant relative to DMSO 
treatment (p-values > 0.05).  Increases of acetyl-H3 with HDAC inhibitors were 
consistent with published reports.  HDAC shRNA treatment did not yield any 
statistically significant increases of acetyl-H3 or RNAP ChIP with the exception of 
HDAC7 and 8 (Figure 2.8B). HDAC7 silencing increased the amount of Acetyl-
Histone H3 and RNAP polymerase ChIP at the SMN2 reporter promoter 
approximately 1.4 fold (p-values < 0.0001 and 0.0006 respectively).  This result is 
comparable to drug treatment and supports the data that HDAC7 primarily 
regulates SMN transcription (Figure 2.5B). 
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Discussion and Future Directions 
 
 HDAC inhibitors including phenylbutyrate and valproic acid are currently or 
have been tested in clinical trials for SMA treatments because of evidence of 
effective increases of full length SMN protein from the SMN2 gene.  The more 
potent compounds do not discriminate between HDAC classes.  These drugs act 
by globally increasing the acetylation state of histones, and may affect the entire 
transcriptome.  Through this mechanism, the HDAC inhibitors increase 
expression of the SMN2 gene and the levels of other modulating proteins such 
as splicing factors.  Ultimately, the goal of increasing full length SMN protein is 
achieved, which makes this class of compounds attractive SMA therapeutic 
drugs.  To gain a better understanding of the contributions of individual HDAC 
proteins, we targeted individual HDAC mRNAs and measured the effects of 
shRNA treatment on SMN2 transcription and splicing.    
The strength of this study was the excellent responsiveness and 
consistency of the HEK293 SMN2-luciferase reporter cell line.  We were able to 
detect changes in SMN2 mRNA and protein in response to individual HDAC 
knockdown as well as class I specific HDAC inhibitor MS-275.  However, other 
cell lines, including primary SMA fibroblasts, were less responsive to these 
treatments.  The observed fold changes of SMN protein and mRNA increases in 
the reporter cells with SAHA and aclarubicin is 2 to 6 fold greater than in  primary 
3813 cells (Cherry, submitted data).  This robust response is most likely due to 
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the high number of copies of the episomal reporter stably maintained in the cells.  
Therefore, it is reasonable to expect a muted response with endogenous SMN 
transcripts in 3813 cells in response to HDAC knockdown.  This SMN2 reporter 
design appears mimic the endogenous context better than any other system to 
date.  Despite the lack of primary cell data, it is our belief that the reporter cell 
line is an excellent tool that yields results that accurately represent the behavior 
of the endogenous SMN genes. 
We were able to demonstrate that targeted silencing of individual HDAC 
proteins was sufficient to increase full length SMN reporter protein.  Our 
experiments support that each HDAC protein individually contributes to 
increasing SMN protein with some overlap of mechanism.  Inhibition of class I 
HDACs, in addition to class II HDACs 4 and 7, appeared to modulate SMN2 
reporter transcription, while exon 7 inclusion was increased with the class II 
HDAC proteins 5 and 6.  As already stated, delineation of the classes of HDAC 
proteins is largely based on yeast protein homology as well as subcellular 
localization.  The class I proteins are exclusively retained within the nucleus while 
class II HDACs shuttle between the cytoplasm and the nucleus.  Therefore, it is 
interesting that silencing of only class II proteins reduced skipping of exon 7.  It is 
possible that these proteins may control the splicing of exon 7 through 
modulation of the acetylation state of specific splicing factors.  We failed to detect 
increase of SR protein levels or acetylation by Western blot (Figure 2.8).   
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Figure 2.9 HDAC Inhibitor Treatment Does Not Induce Detectable Changes 
in SR Protein Acetylation.  Total protein levels and acetylation of SR proteins 
was measured by immunoprecipitation and Western blot.  Anti-SR antibody 
recognizes SRp75, SRp55, SRp40, SRp30a/b (SF2/ASF), and SRp20.  Left 
Panel – Western blot on HDAC inhibitor treated reporter cell lysates. Middle – 
Protein ladder, Right Panel – Western blot of Anti-acetyl Lysine antibody on Anti-
SR immunoprecipiated HDAC inhibitor treated reporter cell lysates.  Any increase 
in total protein was below reliable detection levels.  There was no detected 
acetylation of SR proteins. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
113 
 
114 
 
Undetectable levels of SR protein acetylation could be sufficient to induce 
change in splicing activity or effect secondary post-translational regulatory 
modifications such as phosphorylation.   
These data demonstrate that SMN protein levels can be increased 
through RNAi silencing of individual HDAC proteins.  HDAC2 and HDAC 6 may 
be the most compelling targets for SMA therapy.  Kernochan et al. identified 
HDAC2 as a prime candidate for therapy based largely on its population at the 
SMN2 promoter and potential role in developmental regulation of SMN protein 
levels [129].  Recent works have identified these two HDACs as having 
neuroprotective properties.  Specifically, HDAC2 deficiency resulted in increased 
synapse number as well as improved memory formation [140].  Interestingly, 
HDAC2, rather than HDAC1, populates promoters of genes directly associated 
with synaptic plasticity.  This is also consistent with results obtained probing the 
SMN2-luciferase reporter promoter (Figure 2.2).  Further highlighting the role of 
HDAC2 in synaptic plasticity, SAHA was unable to change synapse numbers in 
HDAC2 deficient mice in contrast to treated wild-type animals [140].  This 
suggests that the transcriptional effect of SAHA on SMN2 transcription may be 
dependent on HDAC2.     
HDAC6 is an interesting drug target because a neuron-specific function 
has been extensively established.  HDAC6 is localized exclusively to the 
cytoplasm and complexes with motor proteins to regulate the acetylation state 
and thereby the stability of microtubules [127].  Acetylation of tubulin increases 
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microtubule stability and reduces tubulin dynamics.  The growth plate of neurons 
is normally void of acetylated tubulin.  Therefore, regulation of HDAC6 levels or 
activity could drastically alter a motor neurons ability to respond to external 
stimuli and either promote or inhibit survival.  HDAC6 inhibition has also been 
shown to enhance neuronal cell survival following injury including promoting 
regeneration [141].  Conversely, HDAC6 was identified as a critical protein that 
when overexpressed is capable of rescuing mis-folded protein accumulation 
related autophagy in neurodegenerative disorders [142, 143].  In some mouse 
models of SMA there is evidence of neurofilament accumulation, however there 
is no evidence of related autophagy [144].  HDAC6’s role in preventing 
autophagy is linked to association with poly-ubiquitinated proteins and promoting 
their degradation.  It is possible that inhibition of HDAC6 alters the stability of the 
SMN protein by countering any mechanism that may promote the proteosome 
based degradation of SMN.   
Interestingly, our analysis revealed that HDAC2 and HDAC6 affect SMN 
mRNA through differing mechanisms, HDAC2 by way of transcription and 
HDAC6 by increasing exon 7 inclusion in addition to transcriptional 
enhancement.  In combination with proposed neuroprotective properties, as well 
as unique mechanisms to increase full length SMN protein, inhibition of one or 
both of the proteins in combination may have profound implications in SMA 
therapy.   
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 The advantage of pan-inhibitor compounds is that transcriptional and 
splicing pathways are being targeted simultaneously.  This is most likely why the 
most potent HDACi drugs currently under investigation for SMA fall into this class 
of compounds.  However, many of these same drugs mentioned, including 
SAHA, MS-275, phenyl butyrate, valproic acid, and sodium butyrate are currently 
used or are in clinical trials for cancer therapy.  It is this class of drugs propensity 
to induce toxic effects on cell cycle and also cell death that make them valuable 
in this context.  Compounds that are more specific in could be more effective in 
SMA therapy and lack potential cytotoxic side effects.   
Development of more effective and targeted therapies depends of the 
complete understanding of HDAC related SMN regulation.  This study has shown 
that inhibition of an individual HDAC is sufficient to increase SMN2 transcription 
as well as promote the inclusion of exon 7.  Therefore, by decreasing the broad 
genomic effects of pan-HDAC inhibitors it may decrease drug toxicity while 
maintaining an acceptable level of SMN activation and possibly other 
neuroprotective effects.  A compound that is capable of achieving this, while 
maintaining potency would be extremely beneficial to SMA patients and families. 
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Final Remarks and Conclusions 
  
 In this study it was demonstrated that RNAi mediated silencing of 
individual HDAC proteins was sufficient to increase activity levels of a SMN2-
luciferase reporter cell line.  There were different mechanisms employed to 
increase steady state levels of the SMN-luciferase fusion protein.  Class I HDACs 
appear to primarily regulate transcription at the SMN promoter.  Class II HDACs 
maintain transcriptional regulation of the promoter, but silencing of HDAC5 and 
HDAC6 also appear to promote inclusion of exon 7.  shRNA response in the 
luciferase and qRT-PCR assays was not as robust as HDAC inhibitor treatment.  
This is most likely due to combinatory effects when multiple HDACs are 
simultaneously targeted by the pan-HDAC inhibitors.  Regardless, it is apparent 
that the individual contributions of HDACs are not equal and suggests multiple, 
possibly overlapping, pathways are at work.  Therefore, it implies that the 
development of more specific HDAC inhibitors could retain the ability to increase 
SMN protein levels, while reducing cytotoxic side effects.   
 This work also used quantitative PCR techniques to characterize the 
effects on SMN-luciferase mRNA by novel chemical compounds identified in high 
throughput screens.  5 compounds and additional chemical analogs were 
identified to activate the SMN2-luciferase reporter.  qRT-PCR was able to identify 
transcriptional activation as the most probable molecular mechanism employed 
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by 3 compounds tested.  The remaining compounds failed to activate reporter 
mRNA and most likely function downstream of protein translation. 
 Following these studies it is important to ask what greater questions may 
have been answers.  In particularly, it is highly relevant to theorize whether more 
potent pan-HDAC inhibitors are a better SMA therapy than more targeted 
selective HDAC inhibitors.  Furthermore, would a targeted RNAi based therapy 
reduce pan-HDAC inhibitor associated toxicity while maintaining acceptable 
levels of SMN protein increase?  The negative side effects of HDAC inhibitors 
are largely associated with the impact on gene expression and acetylation of 
factors associated with the cell cycle and cell survival. 
 In the case of pan-HDAC inhibitors approximately 20% of the 
transcriptome displays altered expression levels.  It is unclear whether or not a 
more selected inhibitor would drastically modify this number, thereby potentially 
reducing toxic effects.  It is possible the number of genes may not change, but 
the amplitude of the changes may be muted.  Maintaining a therapeutic induction 
of SMN2 expression while reducing the global impact of the compound would be 
most beneficial.  The balance of increasing SMN protein levels and SMA 
symptoms versus possible toxic effects of the therapy must be established. 
Oral or IV administration of pan-HDAC inhibitors has a widespread effect 
in all tissues of the body where the drug can penetrate.  Therefore, the chance of 
a negative side effect of drug treatment is enhanced with the number of body 
systems and functions affected.  In SMA, it has been demonstrated that the 
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greatest benefit to survival is obtained when SMN levels in motor neurons is 
increased.  There is functional benefit and strength increase observed in muscle, 
however increased expression in neuronal tissue is sufficient to improve life 
expectancy.  The fold increase of SMN expression in response to shRNA 
mediated knockdown of HDAC proteins is far less than pan-HDAC inhibitors.  
However, with adenovirus or neuronal specific promoter targeting of RNAi to the 
motor neuron it may be possible to enhance quality of life, while minimizing other 
toxic side effects.  Motor neurons are terminally differentiated; so any toxic 
effects on cell cycle may also be minimized in this tissue in response to HDAC 
RNAi.  Alternatively, direct administration of any compound into the spinal cord 
may achieve similar results; however the risk of infection and immune response 
is far greater.  The effect of HDAC knockdown on SMN protein levels needs to be 
studied further and optimized.  These results do not indicate any induction of 
SMN levels in patient fibroblasts.  In vivo testing of optimized short interfering or 
short-hairpin RNAi will give a more clear picture of the potential role individual 
HDACs play in SMA therapy. 
 These experiments established a system to identify RNA based 
mechanisms to increase SMN transcripts in novel luciferase reporter cell lines.  It 
utilized this system to dissect the role that individual HDACs use in SMN 
regulation. The effects of pan-HDAC inhibitors on SMN protein levels were better 
described via the individual HDACs contributions.  This data can be used to 
further develop current SMA therapeutic drugs as well as drive the discovery and 
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synthesis of new compounds.  Furthermore, we have gained greater 
understanding of the basic biology of SMN regulation by HDAC proteins. 
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